<SEC-DOCUMENT>0001193125-16-559626.txt : 20160427
<SEC-HEADER>0001193125-16-559626.hdr.sgml : 20160427
<ACCEPTANCE-DATETIME>20160427163204
ACCESSION NUMBER:		0001193125-16-559626
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20160609
FILED AS OF DATE:		20160427
DATE AS OF CHANGE:		20160427
EFFECTIVENESS DATE:		20160427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		161595785

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d104091ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Rule
14a-101) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement Pursuant to Section&nbsp;14(a) of the </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities Exchange Act of 1934 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Filed by the Registrant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Filed by a Party other than the Registrant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Preliminary Proxy Statement </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Definitive Proxy Statement </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Definitive Additional Materials </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting Material Pursuant to &#167; 240.14a-12 </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Registrant as Specified In Its Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Person(s) Filing Proxy
Statement if Other Than the Registrant) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top">No fee required. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Title of each class of securities to which transaction applies: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Aggregate number of securities to which transaction applies: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Proposed maximum aggregate value of transaction: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Total fee paid: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Fee paid previously with preliminary materials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Amount Previously Paid: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Form, Schedule or Registration Statement No.: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Filing Party: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Date Filed: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;27, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholders of ARCA
biopharma, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of ARCA
biopharma, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;ARCA&#148;). The meeting will be held on Thursday, June&nbsp;9, 2016, at 9:00 a.m. local time at the Boulder Marriott Hotel, 2660 Canyon Boulevard, Boulder, CO 80302. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The matters scheduled to be considered at the meeting are (1)&nbsp;to elect the nominee of the Company&#146;s Board of Directors (the
&#147;Board of Directors&#148;), Dr.&nbsp;Linda Grais, to the Board of Directors to hold office until the 2019 Annual Meeting of Stockholders, (2)&nbsp;to ratify the selection by the Audit Committee of the Board of Directors (the &#147;Audit
Committee&#148;) of KPMG LLP (&#147;KPMG&#148;) as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2016, (3)&nbsp;to approve the Amended and Restated ARCA 2013 Equity Incentive Plan,
(4)&nbsp;to approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in this proxy statement, and (5)&nbsp;to conduct any other business properly brought before the meeting. These items of business
are more fully described in this proxy statement that you are encouraged to read in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the Securities and
Exchange Commission (&#147;SEC&#148;) rule (&#147;Notice and Access Rule&#148;) that allows companies to furnish their proxy materials (including the form of proxy, this proxy statement and our Annual Report on Form 10-K for the fiscal year ended
December&nbsp;31, 2015, filed with the SEC on March&nbsp;17, 2016) over the Internet, we intend to send a Notice of Internet Availability of Proxy Materials (&#147;Notice&#148;) on or about April&nbsp;28,&nbsp;2016 to our stockholders of record as
of April&nbsp;12, 2016. We will also provide access to our proxy materials over the Internet by April&nbsp;28, 2016. As a result of the Notice and Access Rule, all stockholders receiving the Notice have the ability to access the proxy materials over
the Internet and request to receive a paper copy of the proxy materials by mail. Instructions on how to access the proxy materials over the Internet or to request a paper copy may be found on the Notice. In addition, the Notice contains instructions
on how stockholders may request to receive proxy materials electronically by e-mail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All stockholders are cordially invited to attend the
Annual Meeting in person. Whether or not you expect to attend the Annual Meeting, please vote, as instructed in the Notice of Internet Availability of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure
your representation at the Annual Meeting. Alternatively, you may follow the procedures outlined in the Notice of Internet Availability of Proxy Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy,
you may still vote in person if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from
that record holder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g104091g03c53.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>CHRISTOPHER OZEROFF</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Secretary,&nbsp;Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;General&nbsp;Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON JUNE&nbsp;9, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">Notice is hereby given that the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of ARCA biopharma, Inc., a Delaware
corporation (the &#147;Company&#148; or &#147;ARCA&#148;) will be held on Thursday, June&nbsp;9, 2016, at 9:00 a.m. local time at the Boulder Marriott Hotel, 2660 Canyon Boulevard, Boulder, CO 80302, for the following purposes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To elect the Board of Directors&#146; nominee, Dr.&nbsp;Linda Grais, to the Board of
Directors to hold office until the 2019 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To ratify the
selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To approve the Amended and Restated ARCA 2013 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To approve, on an advisory basis, the compensation of the Company&#146;s named executive
officers, as disclosed in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To conduct any other business properly
brought before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the proxy statement accompanying this Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">The record date for the Annual Meeting is April&nbsp;12, 2016. Only stockholders of record at the close of business on that date may vote at
the meeting or any adjournment thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board of Directors:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g104091g03c53.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>CHRISTOPHER OZEROFF</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Secretary,&nbsp;Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;General&nbsp;Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>ESTMINSTER</SMALL>, CO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>PRIL</SMALL>&nbsp;27, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Pursuant to the Internet proxy rules promulgated by the Securities and Exchange Commission, the Company has elected to
provide access to its proxy materials over the Internet. Accordingly, stockholders of record at the close of business on April&nbsp;12, 2016, will receive a Notice of Internet Availability of Proxy Materials and may vote at the Annual Meeting and
any adjournment or postponement thereof. The Company expects to mail the Notice of Internet Availability of Proxy Materials on or about April&nbsp;28, 2016. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>All stockholders are cordially invited to attend the Annual Meeting in person. Whether or not you expect to attend the
Annual Meeting, please vote, as instructed in the Notice of Internet Availability of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure your representation at the annual meeting. Alternatively, you may
follow the procedures outlined in the Notice of Internet Availability of Proxy Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting.
Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
2016 ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JUNE 9, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This proxy statement (this &#147;Proxy Statement&#148;) is being furnished to holders of ARCA biopharma, Inc. (sometimes referred to as the
&#147;Company,&#148; &#147;ARCA,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148;) common stock, par value $0.001 per share (the &#147;Common Stock&#148;). Proxies are being solicited on behalf of the Board of Directors of ARCA to be used
at the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on Thursday, June&nbsp;9, 2016, at 9:00 a.m. local time at the Boulder Marriott Hotel, 2660 Canyon Boulevard, Boulder, CO 80302, and at any postponement or adjournment
thereof, for the purposes set forth in the Notice of Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ARCA is using the Securities and Exchange Commission
(the &#147;SEC&#148;) rule that allows companies to furnish their proxy materials over the Internet. As a result, we intend to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) instead of a paper
copy of the proxy materials (including the form of proxy, this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2015, filed with the SEC on March&nbsp;17, 2016 (the &#147;2015 Annual Report&#148;),
collectively, the &#147;Proxy Materials&#148;) on or about April&nbsp;28, 2016. We will also provide access to our Proxy Materials over the Internet by April&nbsp;28, 2016. By furnishing the Notice to our stockholders of record, you <B><I><U>will
not</U></I></B> receive a printed copy of the Proxy Materials in the mail. Instead, the Notice instructs you on how to access and review all of the important information contained in the Proxy Statement and Annual Report electronically or to receive
a printed version in the mail. The Notice also instructs you on how you may submit your proxy over the Internet, by toll-free number or in person at the Annual Meeting. Subsequent to receiving the Notice, all stockholders have the ability to access
the Proxy Materials over the Internet and request to receive a paper copy of the Proxy Materials by mail. Instructions on how to access the Proxy Materials over the Internet or to request a paper copy may be found on the Notice. In addition, the
Notice contains instructions on how stockholders may request to receive Proxy Materials electronically by <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All stockholders may view and print ARCA&#146;s proxy statement and the 2015 Annual Report, which are available at www.arcabiopharma.com. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice regarding the availability of the Proxy Materials on the Internet? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described above, pursuant to rules adopted by the SEC, we have elected to provide access to the Proxy Materials over the Internet.
Accordingly, on or about April&nbsp;28, 2016, we expect to send the Notice to ARCA&#146;s stockholders of record. The Board of Directors is soliciting your proxy to vote at the Annual Meeting. All stockholders will have the ability to access the
Proxy Materials on the website referred to in the Notice or request to receive a printed or electronic set of the Proxy Materials. Instructions on how to access the Proxy Materials over the Internet or to request a printed copy may be found in the
Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The meeting will be held on Thursday, June&nbsp;9, 2016, at 9:00 a.m. local time at the Boulder Marriott Hotel, 2660 Canyon Boulevard,
Boulder, CO 80302. Directions to the Annual Meeting may be found at www.arcabiopharma.com. Information on how to vote in person at the Annual Meeting is discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;12, 2016, will be entitled to vote at the Annual Meeting. On this record
date, there were 9,066,348 shares of Common Stock outstanding and entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your
Name</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, on April&nbsp;12, 2016, your shares of our Common Stock were registered directly in your name with ARCA&#146;s transfer
agent, Computershare Trust Company N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to vote by proxy over the
telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker or Bank</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, on April&nbsp;12, 2016, your shares of our Common Stock were held, not in your name, but rather in an account at a brokerage firm, bank,
dealer, or other similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the
stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting.
However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are four
matters scheduled for a vote: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Election of one director; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ratification of selection by the Audit Committee of the Board of Directors of KPMG LLP (&#147;KPMG&#148;) as independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2016; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Approval of the Amended and Restated ARCA 2013 Equity Incentive Plan; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Approval, on an advisory basis, of the compensation of the Company&#146;s named executive officers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What
if another matter is properly brought before the meeting? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for
consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You may either vote
&#147;For&#148; the nominee to the Board of Directors or you may &#147;Withhold&#148; your vote for the nominee. For all other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for
voting are fairly simple: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy over the telephone, vote by proxy through the
Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we
will vote your shares as you direct. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To vote over the telephone, dial toll-free <B>1-800-652-VOTE (8683)</B>&nbsp;using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the
Notice. Your vote must be received by 1:00 a.m. Mountain Time on June&nbsp;9, 2016, to be counted. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To vote through the Internet, go to <B>http://www.investorvote.com/ABIO</B> to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be
received by 1:00 a.m. Mountain Time on June&nbsp;9, 2016, to be counted. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker or
Bank </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a
Notice containing voting instructions from that organization rather than from ARCA. Simply follow the voting instructions in the Notice to ensure that your vote is counted. To vote in person at the Annual Meeting, you must obtain a valid proxy from
your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and
correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your access to the Internet, such as usage charges from Internet access providers and telephone companies. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On each
matter to be voted upon, you have one vote for each share of Common Stock you owned as of April&nbsp;12, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I return a proxy card or
otherwise vote but do not make specific choices? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you return a signed and dated proxy card or otherwise vote without marking voting
selections, your shares will be voted, as applicable, &#147;For&#148; the election of the nominee for director and &#147;For&#148; Proposals 2, 3 and 4. If any other matter is properly presented at the meeting, your proxy holder (one of the
individuals named on your proxy card) will vote your shares using his or her best judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, the directors and employees may also solicit
proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one Notice? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting
instructions on each Notice to ensure that all of your shares are voted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after submitting my proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke
your proxy in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may submit another properly completed proxy card with a later date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may grant a subsequent proxy by telephone or through the Internet. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may send a timely written notice that you are revoking your proxy to ARCA&#146;s Secretary at 11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Your most current proxy card or telephone or Internet proxy is the one that is counted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are stockholder proposals due for next year&#146;s annual meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by December&nbsp;29, 2016, to
ARCA&#146;s Secretary at 11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020. If you wish to submit a proposal that is not to be included in next year&#146;s proxy materials or nominate a director, you must do so by no earlier than
March&nbsp;11, 2017, and no later than April&nbsp;10, 2017. You are also advised to review the Company&#146;s Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Votes will be
counted by the inspector of election appointed for the meeting. For Proposal 1, to elect a new director, votes &#147;For&#148; and &#147;Withhold&#148; will be counted. For Proposals 2, 3 and 4, votes &#147;For&#148; and &#147;Against&#148;,
abstentions and broker non-votes will be counted. Abstentions will be counted towards the vote total for Proposals 2, 3 and 4, and will have the same effect as &#147;Against&#148; votes. Broker non-votes have no effect and will not be counted
towards the vote total for any proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are &#147;broker non-votes&#148;? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Broker non-votes occur when a beneficial owner of shares held in &#147;street name&#148; does not give instructions to the broker or nominee
holding the shares as to how to vote. Generally, if shares are held in street name, the beneficial owner of the shares is entitled to give voting instructions to the broker or nominee holding the shares. If the beneficial owner does not provide
voting instructions, the broker or nominee can still vote the shares with respect to matters that are considered to be &#147;routine,&#148; but not with respect to &#147;non-routine&#148; matters. Under the rules and interpretations of the New York
Stock Exchange (&#147;NYSE&#148;), &#147;non-routine&#148; matters are matters that may substantially affect the rights or privileges of shareholders, such as mergers, shareholder proposals and elections of directors, even if not contested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;1, for the election of a director. For this proposal, the nominee receiving the most &#147;For&#148; votes (from the holders of votes of shares present in person or represented by proxy and entitled to
vote on the election of directors) will be elected. Only votes &#147;For&#148; or &#147;Withheld&#148; votes will affect the outcome. Broker non-votes will have no effect. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;2, to ratify the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for fiscal year 2016. This proposal must receive &#147;For&#148; votes from the holders of a
majority of shares present and entitled to vote either in person or by proxy. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker non-votes will have no effect. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;3, to approve the Amended and Restated ARCA 2013 Equity Incentive Plan. This proposal must receive &#147;For&#148; votes from the holders of a majority of shares present and entitled to vote either in
person or by proxy. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker non-votes will have no effect. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;4, an advisory approval of the compensation of the Company&#146;s named executive officers. This proposal must receive &#147;For&#148; votes from the holders of a majority of shares present and
entitled to vote either in person or by proxy to be considered to be approved. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker non-votes will have no effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the quorum requirement? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A
quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding a majority of the outstanding shares of Common Stock entitled to vote are present at the meeting in person or represented by proxy. On the
record date, April&nbsp;12, 2016, there were 9,066,348 shares of Common Stock outstanding and entitled to vote. Thus, the holders of 4,533,174 shares of Common Stock must be present in person or represented by proxy at the meeting to have a quorum.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank
or other nominee) or if you vote in person at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting in person or represented by
proxy may adjourn the meeting to another date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on
Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form&nbsp;8-K within four business days after the meeting, we intend to file a <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form&nbsp;8-K to publish the final results. </P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NO PERSON IS AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION OTHER THAN THOSE CONTAINED IN THIS PROXY STATEMENT, AND, IF
GIVEN OR MADE, SUCH INFORMATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED. THE DELIVERY OF THIS PROXY STATEMENT SHALL, UNDER NO CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF ARCA SINCE THE DATE OF THIS
PROXY STATEMENT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>LECTION</SMALL> O<SMALL>F</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Amended and Restated Certificate of Incorporation provides that the Board of Directors is divided into three classes to
provide for staggered terms and that each director will serve for a term of three years or less, depending on the class to which the Board of Directors has assigned a director not previously elected by the stockholders. There are currently no
vacancies on the Board of Directors. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies
created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is duly elected and qualified. The Company may reduce or increase the size of the Board of
Directors by resolution adopted by the affirmative vote of a majority of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently two Class III directors,
whose terms expire at the annual stockholders&#146; meeting in 2018, two Class II directors whose terms expire at the annual stockholders&#146; meeting in 2017, and one Class I director, whose term expires at the annual stockholders&#146; meeting in
2016. The Board of Directors has nominated one Class I director, Dr.&nbsp;Linda Grais, for election to the Board of Directors, for a three-year term ending on the date of the annual meeting in 2019 or until her successor is duly elected and
qualified or appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If elected at the Annual Meeting, Dr.&nbsp;Grais would serve until the 2019 annual meeting and until her
successor has been duly elected and qualified, or, if sooner, until the director&#146;s death, resignation or removal. It is the Company&#146;s policy to encourage directors and nominees for director to attend the Annual Meeting. Three of the
Company&#146;s directors then on the Board of Directors attended the 2015 Annual Meeting of Stockholders in person, and two attended by telephone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on
the election of directors. The nominee receiving the highest number of affirmative votes will be elected. The person nominated for election has agreed to serve if elected. The Company&#146;s management has no reason to believe that the nominee will
be unable to serve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Qualifications and Diversity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The below paragraphs provide information, as of the date of this proxy statement, about the nominee and current members of the Board of
Directors, including age, all positions currently held, principal occupation and business experience for the past five years. In addition to the information presented regarding each nominee&#146;s specific experience, qualifications, attributes and
skills that led the Board of Directors to conclude that such director or nominee should be able to serve as a director, the Board of Directors also believes that all of the directors and nominees have a reputation of integrity, honesty and adherence
to high ethical standards. They each have demonstrated business acumen and an ability to exercise sound judgment as well as a commitment to service to ARCA and the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee considers diversity in the director identification and nomination process. The Nominating
and Corporate Governance Committee seeks nominees with a broad diversity of experience, professions, skills, geographic representation and backgrounds. Such Committee does not assign specific weights to particular criteria and no particular
criterion is necessarily applicable to all prospective nominees. ARCA believes that the backgrounds and qualifications of the directors, considered as a group, should provide a significant composite mix of experience, knowledge and abilities that
will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of race, religion, national origin, sexual orientation, disability or any other basis proscribed by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OMINEE</SMALL> <SMALL>FOR</SMALL> E<SMALL>LECTION</SMALL> <SMALL>FOR</SMALL>
<SMALL>A</SMALL> T<SMALL>HREE</SMALL>-<SMALL>YEAR</SMALL> T<SMALL>ERM</SMALL> E<SMALL>XPIRING</SMALL> <SMALL>AT</SMALL> <SMALL>THE</SMALL> 2019 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> N<SMALL>AMED</SMALL>
N<SMALL>OMINEE</SMALL>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Linda Grais, M.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Grais, age 59, has served as a member of the Board of Directors since May 2007. Dr.&nbsp;Grais has been a director of Ocera
Therapeutics, Inc., a public biopharmaceutical company, since January 2008 and became President and Chief Executive Officer of Ocera in June 2012. Dr.&nbsp;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005
until February 2011. From July 1998 to July 2003, Dr.&nbsp;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&nbsp;&amp;
Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&nbsp;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of
California, San Francisco. Dr.&nbsp;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September 2015, Dr.&nbsp;Grais has served on the board
of PRA Health Sciences, a public contract research organization. Dr.&nbsp;Grais is an appropriate nominee to the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and
senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of the Company&#146;s business from her service on the Board of Directors of the
Company since 2007. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL>
2017 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Michael R. Bristow, M.D., Ph.D. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bristow, age 71, was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr.&nbsp;Bristow
has also served as the Company&#146;s President and Chief Executive Officer since July 2009. Previously, Dr.&nbsp;Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the
Company&#146;s Chief Science and Medical Officer from November 2006 to July 2009. Dr.&nbsp;Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October
1991. Dr.&nbsp;Bristow was one of the founders of Myogen, Inc. and served as Myogen&#146;s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen
by Gilead Sciences, Inc. in November 2006. Dr.&nbsp;Bristow is an appropriate member of the Company&#146;s Board of Directors given his extensive experience and expertise as a cardiologist, medical researcher and drug developer in the field of
cardiovascular medicine, and heart failure specifically, and his experience as a founder and manager of cardiovascular-focused, public pharmaceutical company. Dr.&nbsp;Bristow also has extensive experience with, and knowledge of, ARCA&#146;s
business, as the founder and former Chief Science and Medical Officer of the Company, and the current President and Chief Executive Officer of ARCA, and as a member of the Board of Directors of ARCA since the founding of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Robert E. Conway </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Conway, age
62, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. Mr.&nbsp;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a
publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&nbsp;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&nbsp;Conway held
various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which
was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eResearch Technology, Inc., a private company, and from 2015 to the present, he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company.
Mr.&nbsp;Conway also serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr.&nbsp;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC. Mr.&nbsp;Conway received
a B.S. in accounting from Marquette University in 1976. He is an appropriate member of the Board of Directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate
finance, governance, accounting and public company compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL>
O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2018 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Raymond L. Woosley, M.D., Ph.D.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Woosley, age 73, was appointed to the Board of Directors in July 2013.&nbsp;Dr.&nbsp;Woosley is currently the President
Emeritus of the Critical Path Institute (C-Path), a non-profit, public-private partnership with the Federal Food and Drug Administration, of which he was a founder in November 2004, and where he served as President, Chief Executive Officer and
Chairman of the board of directors from 2005 to 2011.&nbsp;Since 2012, Dr.&nbsp;Woosley has also been the Director of CredibleMeds Worldwide, an independent, nonprofit research and education organization.&nbsp;Since 2001, Dr.&nbsp;Woosley has also
been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center (UAHSC), and, since 2012, Professor Emeritus, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of
Medicine from 2001 to 2002. From 1988 to 2001, Dr.&nbsp;Woosley was a professor of medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division
Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994.&nbsp;Dr.&nbsp;Woosley earned his Ph.D. in Pharmacology from the University of Louisville and his M.D. from the University of Miami.&nbsp;Dr.&nbsp;Woosley&#146;s research
has been published in over 265 peer-reviewed publications and 50 book chapters.&nbsp;Dr.&nbsp;Woosley is an appropriate member of the Board of Directors, given his expertise and experience in cardiovascular clinical pharmacology, anti-arrhythmic
therapeutics, pharmacogenetic drug development and therapeutic regulatory approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dan J. Mitchell </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell, age 59, was appointed to the Board of Directors in February 2014. He founded, and is a manager of Sequel Venture Partners,
L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr.&nbsp;Mitchell was a founder of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner from
October 1986 until 2006, and he was in the Venture Capital Division of the Trust Department of the First National Bank of Chicago from 1983 to 1985. He currently serves on the board of directors of GlobeImmune, Inc., a publicly traded
biopharmaceutical company, and several private companies. Mr.&nbsp;Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. Mr.&nbsp;Mitchell is an appropriate member of the Board of
Directors given his expertise and experience in the pharmaceutical industry, pharmaceutical development, and in corporate finance and governance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I<SMALL>NFORMATION</SMALL> R<SMALL>EGARDING</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>
<SMALL>AND</SMALL> C<SMALL>ORPORATE</SMALL> G<SMALL>OVERNANCE</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NDEPENDENCE</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As required under the Nasdaq Stock Market (&#147;Nasdaq&#148;)
listing standards, a majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent,&#148; as affirmatively determined by the board of directors. Our Board of Directors consults with the Company&#146;s
counsel to ensure that the Board of Directors&#146; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#147;independent,&#148; including those set forth in pertinent listing standards
of the Nasdaq, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Consistent with these considerations, after review of all relevant identified transactions
or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following four
directors are independent directors within the meaning of the applicable Nasdaq listing standards: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr. Conway, Dr.&nbsp;Grais, Mr.&nbsp;Mitchell and Dr.&nbsp;Woosley. In making this determination, the Board of Directors found that none of the directors or nominees for director had a material
or other disqualifying relationship with the Company. Dr.&nbsp;Bristow, the Company&#146;s President and Chief Executive Officer is not an independent director by virtue of his relationship with the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>OARD</SMALL> L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has structured its Board of Directors in a way that the Company believes effectively serves its objectives of corporate governance
and management oversight. The Company separates the roles of Chief Executive Officer and Chairman of the Board of Directors in recognition of the differences between the two roles. The Company believes that the Chief Executive Officer should be
responsible for the day to day leadership and performance of the Company, while the Chairman of the Board of Directors should work with the Chief Executive Officer and the rest of the Board of Directors to set the strategic direction for the Company
and provide guidance to, and oversight of the Chief Executive Officer. The Chairman also sets the agenda for meetings of the Board of Directors and presides over them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Conway, who is an independent director, was elected Chairman of the Board of Directors in 2014. In this capacity, Mr.&nbsp;Conway,
among other things, calls and presides over Board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&nbsp;Conway can effectively coordinate between the Board and management regarding risk
management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the Board of Directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the
work of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>OLE</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL> <SMALL>IN</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> <SMALL>AND</SMALL> R<SMALL>ISK</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One of the Board of Directors&#146; key functions is informed oversight of the Company&#146;s risk management process. The Board of Directors
does not have a standing risk management committee, but rather administers this oversight function directly through the Board of Directors as a whole, as well as through various standing committees of the Board of Directors that address risks
inherent in their respective areas of oversight. In particular, while the Board of Directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial
risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance
with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#146;s accounting and financial reporting processes. The nominating and corporate governance committee of the Board of Directors (the &#147;Nominating and
Corporate Governance Committee&#148;) monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. The compensation committee of the Board of
Directors (the &#147;Compensation Committee&#148;) assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk-taking. The entire Board of Directors and its committees address risk management
issues from time-to-time and at least annually meet with the employees responsible for risk management in the committees&#146; respective areas of oversight. Both the Board of Directors as a whole and the various standing committees receive periodic
reports from the employees responsible for risk management, as well as incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board of Directors as
quickly as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>M<SMALL>EETINGS</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors met six times during the 2015 fiscal year. The independent members of the Board of Directors met separately as
a group in connection with each of the four regularly scheduled board meetings in 2015. All members of the Board of Directors attended at least 75% of the meetings of the Board of Directors and at least 75% the meeting of the committees of the Board
of Directors of which each director was a member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NFORMATION</SMALL> R<SMALL>EGARDING</SMALL> C<SMALL>OMMITTEES</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has three standing
committees: the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal year 2015, for each of the committees of the Board of
Directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;Compensation&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominating&nbsp;and<BR>Corporate<BR>&nbsp;&nbsp;&nbsp;&nbsp;Governance&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Michael&nbsp;R.
Bristow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Linda Grais</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;X*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Raymond&nbsp;L. Woosley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;X*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Robert&nbsp;E. Conway</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;X*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Dan&nbsp;J. Mitchell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total meetings in fiscal 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Current Committee Chairperson. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Below is a description of each committee of the Board of
Directors. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board of Directors has determined that each member of each committee meets the
applicable Nasdaq rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee was
established by the Board of Directors in accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), to oversee the Company&#146;s corporate accounting and financial reporting processes
and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm;
determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered
public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent registered public accounting
firm on the Company&#146;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent registered public accounting firm regarding
the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting
controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review the Company&#146;s annual audited financial statements and quarterly
financial statements with management and the independent registered public accounting firm, including a review of the Company&#146;s disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations.&#148; The Audit Committee is currently composed of three directors: Mr.&nbsp;Conway (chair), Mr.&nbsp;Mitchell and Dr.&nbsp;Woosley. The Audit Committee met four times during the fiscal year. The Board of Directors has adopted a written
charter of the Audit Committee that is available to stockholders on the Company&#146;s website at www.arcabiopharma.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of
Directors reviews the Nasdaq listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule
5605(c)(2)(A)(i) and (ii)&nbsp;of the Nasdaq listing standards). The Board of Directors has also determined that Mr.&nbsp;Conway qualifies as an &#147;audit committee financial expert,&#148; as defined in applicable SEC rules. The Board of Directors
made a qualitative assessment of Mr.&nbsp;Conway&#146;s level of knowledge and experience based on a number of factors, including his prior experience, business acumen and independence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee of the Board of Directors<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2015,
with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Statement on Auditing Standards No.&nbsp;61, as amended (AICPA, <I>Professional
Standards</I>, Vol. 1, AU section 380), as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) in Rule 3200T. The Audit Committee has also received the written disclosures and the letter from the independent registered
public accounting firm required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#146;s communications with the Audit Committee concerning independence, and has discussed with the independent
registered public accounting firm the accounting firm&#146;s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in the Company&#146;s Annual Report on
Form 10-K for the fiscal year ended December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mr.&nbsp;Robert Conway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mr.&nbsp;Dan Mitchell&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Raymond Woosley </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation
Committee is currently composed of three directors: Mr.&nbsp;Robert Conway, Dr.&nbsp;Linda Grais (chair) and Dr.&nbsp;Raymond Woosley. All members of the Compensation Committee are independent, as independence is currently defined in Rule 5605(a)(2)
of the Nasdaq listing standards. The Compensation Committee met five times during the fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at www.arcabiopharma.com.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Board of Directors acts on behalf of the Board of Directors to review, adopt and oversee the
Company&#146;s compensation strategy, policies, plans and programs, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing succession planning for senior management of the Company, including a review of the performance and advancement potential of current and future senior management and succession plans for each and
recommending, as appropriate, the retention of potential succession candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing the overall compensation structure of the Company and evaluating and recommending changes to the Company&#146;s compensation philosophies and strategies; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving performance-based compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering, reviewing, and approving all executive compensation programs or plans, and all of the Company&#146;s incentive compensation and stock plans and awards thereunder of the Company, including amendments to
the programs, plans or awards made thereunder; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing and approving the Report of the Compensation Committee to be included as part of the Company&#146;s annual meeting proxy statement, to the extent required. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act of
1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Processes and Procedures </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Typically, the Compensation Committee meets on a regular basis as it deems appropriate. The agenda for each meeting is usually developed by
the Chair of the Compensation Committee. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the
Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during,
any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of
executive and director compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2013, the Company&#146;s Compensation Committee reviewed the Company&#146;s executive compensation in light of general market
conditions in the life science industry. As part of this review process, the Compensation Committee identified a peer group of biotechnology companies that it viewed as having a similar profile to ARCA at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In setting 2015 base salary and cash bonus award amounts for the ARCA Named Executive Officers, the Compensation Committee took into account
peer group data and factors specific to the Company, and targeted cash compensation to be consistent with these metrics. The Compensation Committee recommended, and the Board of Directors approved, a base salary of $286,759 for Dr.&nbsp;Bristow, the
Company&#146;s President and Chief Executive Officer, a base salary of $285,600 for Mr.&nbsp;Keuer, the Company&#146;s Chief Operating Officer, and a base salary of $280,273 for Mr.&nbsp;Ozeroff, the Company&#146;s Senior Vice President and General
Counsel, for the fiscal year 2015. In early 2016, Compensation Committee recommended and the Board of Directors approved cash bonuses based on previous performance for the Named Executive Officers (as defined below), and also approved increases to
Named Executive Officer salaries for the fiscal year 2016 as described in below under &#147;Executive Compensation&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Historically,
the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. The
Company has deferred equity awards for 2016 and future performance pending final approval of ARCA&#146;s amended and restated 2013 Equity Incentive Plan by the Company&#146;s stockholders, but expects to make such grants later in the year. However,
the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of the Company&#146;s compensation strategy, potential
modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#146;s process comprises two related elements: the determination of compensation
levels and the establishment of performance objectives for the current year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee reviews and approves the
compensation of the Chief Executive Officer and the other executive officers of the Company, including annual base salaries, annual and long-term incentive or bonus awards, employment agreements, and severance and change in control
agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations
submitted to the Compensation Committee by the Chief Executive Officer. The Compensation Committee evaluates the performance of the Chief Executive Officer in light of Company and individual goals and objectives, and makes appropriate
recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other non-employee members of the Board of Directors and lead the Board of Directors in an overall review
of the Chief Executive Officer&#146;s performance in an executive session of non-employee members of the Board of Directors. If the compensation for the Chief Executive Officer or any other executive officer is governed by an employment agreement,
the Compensation Committee approves such employment agreement and any amendments thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For all executives as part of its deliberations, the Compensation Committee may review and
consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical
scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of
the Company (consistent with criteria approved by the Board of Directors), reviewing and evaluating incumbent directors, recommending to the Board of Directors candidates for election to the Board of Directors, making recommendations to the Board of
Directors regarding compensation for service on the Board of Directors and the committees thereof, making recommendations to the Board of Directors regarding the membership of the committees of the Board of Directors, assessing the performance of
the Board of Directors and developing a set of corporate governance principles for the Company. The Nominating and Corporate Governance Committee is currently composed of three directors, Dr.&nbsp;Grais, Mr.&nbsp;Mitchell and Dr.&nbsp;Woosley
(chair). All members of the Nominating and Corporate Governance Committee in 2015 were independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met four
times during the 2015 fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at <U>www.arcabiopharma.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee periodically reviews the compensation of non-employee Directors for service on the Board of
Directors and committees thereof. In 2015, the Nominating and Corporate Governance Committee began a review of its Director compensation levels in light of general market conditions in the life science industry and in comparison to other clinical
stage biopharmaceutical companies. In early 2016, the Nominating and Corporate Governance Committee recommended, and the Board of Directors approved, revised compensation for non-employee Directors, discussed in &#147;Director Compensation&#148;
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees.
Before recommending an individual to the Board of Directors for membership on the Board of Directors, the Nominating and Corporate Governance Committee canvasses its members and the Company&#146;s management team for potential candidates for the
Board of Directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate
Governance Committee will consider stockholders&#146; recommendations for nominees to serve as director if notice is timely received by the Secretary of the Company. Candidates nominated by stockholders will be evaluated in the same manner as other
candidates. The Nominating and Corporate Governance Committee keeps the Board of Directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if
the stockholder notice of nomination is timely made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although the Board of Directors has not adopted a fixed set of minimum
qualifications for candidates for membership on the Board of Directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#146;s education,
professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, the reasonable availability of the potential member to devote
time to the affairs of the Company, as well as any other criteria deemed relevant by the Board of Directors or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify
these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board of Directors, the operating requirements of the Company and the long-term interests of stockholders. In
conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given the current needs of the Board of Directors and the Company, to maintain a
balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that Board of Directors members come from a variety of backgrounds and experiences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of incumbent directors whose terms of office are set to expire, the Nominating and
Corporate Governance Committee reviews these directors&#146; overall contributions to the Company and the Board of Directors during their terms, including level of attendance, level of participation, quality of performance and contribution to the
Board of Directors&#146; responsibilities and actions, and any relationships and transactions that might impair the directors&#146; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also
determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and
Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board of Directors. The Nominating and Corporate
Governance Committee meets to discuss and consider the candidates&#146; qualifications and then determines whether to recommend a nominee to the Board of Directors by majority vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for
election to the Board of Directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90 days before the one year anniversary date of ARCA&#146;s
last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#146;s business experience for at least the previous five years, complete biographical information, a
description of the proposed nominee&#146;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#146;s stock. Any such submission must be accompanied by the written consent of
the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2015, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL>
D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to communicate with the Board of Directors may do so by e-mail by using the following
email address: <U>directors@arcabiopharma.com</U>; or by mail by following the directions as set forth on ARCA&#146;s website at www.arcabiopharma.com, under the section titled &#147;Corporate Governance&#148; and the subsection titled
&#147;Governance Documents&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ODE</SMALL> <SMALL>OF</SMALL> B<SMALL>USINESS</SMALL> C<SMALL>ONDUCT</SMALL> <SMALL>AND</SMALL>
E<SMALL>THICS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to all
officers, directors and employees. The Code of Business Conduct and Ethics is available on the Company&#146;s website at www.arcabiopharma.com. If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants any
waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form 8-K required by
applicable law or Nasdaq listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ATIFICATION</SMALL> <SMALL>OF</SMALL> S<SMALL>ELECTION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> I<SMALL>NDEPENDENT</SMALL>
R<SMALL>EGISTERED</SMALL> P<SMALL>UBLIC</SMALL> A<SMALL>CCOUNTING</SMALL> F<SMALL>IRM</SMALL> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected KPMG
LLP (&#147;KPMG&#148;) as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2016, and has further directed that management submit the selection of the independent registered public
accounting firm for ratification by the stockholders at the Annual Meeting. KPMG has audited the Company&#146;s fiscal year financial statements since 2009. Representatives of KPMG are expected to be present at the Annual Meeting. They will have an
opportunity to make a statement if they so desire and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the Company&#146;s
Bylaws nor other governing documents or law require stockholder ratification of the selection of KPMG as the Company&#146;s independent registered public accounting firm. However, the Board of Directors is submitting the selection of KPMG to the
stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in
its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual
Meeting will be required to ratify the selection of KPMG. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>RINCIPAL</SMALL> A<SMALL>CCOUNTANT</SMALL> F<SMALL>EES</SMALL> <SMALL>AND</SMALL> S<SMALL>ERVICES</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table represents aggregate fees billed, or expected to be billed, to the Company for the fiscal year ended December&nbsp;31,
2015, and December&nbsp;31, 2014, by KPMG, the Company&#146;s independent registered public accounting firm. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year<BR>Ended&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year<BR>Ended&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Audit Fees (1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$166,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$140,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Audit-related Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tax Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">All Other Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">All Other Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Total Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$166,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$140,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit Fees include fees for the (i)&nbsp;audit of the financial statements included in our Form 10-K for our fiscal years ended December 31, 2015, and December&nbsp;31, 2014, (ii)&nbsp;review of interim financial
statements included on Forms 10-Q and (iii)&nbsp;attest, consent and review services normally provided by the accountant in connection with SEC filings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All fees described above were approved by the Audit Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>RE</SMALL>-A<SMALL>PPROVAL</SMALL> P<SMALL>OLICIES</SMALL> <SMALL>AND</SMALL>
P<SMALL>ROCEDURES</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above services performed by the independent registered public accounting firm were pre-approved in
accordance with the pre-approval policy and procedures adopted by the Audit Committee. This policy describes the permitted audit, audit-related, tax, and other services that the independent registered public accounting firm may perform. The policy
also requires that the independent registered public accounting firm provide in writing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual description of all relationships between the independent registered public accounting firm and the client that may reasonably be thought to bear on independence; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confirm that, in the independent registered public accounting firm&#146;s professional judgment, the independent registered public accounting firm is independent of the client under SEC requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discuss with the Audit Committee the independent registered public accounting firm&#146;s independence and the potential effects on its independence of performing any non-audit related services. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The services expected to be performed by the independent registered public accounting firm during the subsequent fiscal year are presented to
the Audit Committee for pre-approval. Any pre-approval must describe, in writing, the particular service or category of services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Requests for audit, audit-related, tax, and other services not contemplated by those pre-approved services must be submitted to the Audit
Committee for specific pre-approval. Generally, pre-approval is considered at the Audit Committee&#146;s regularly scheduled meetings. However, the authority to grant specific pre-approval between meetings, as necessary, has been delegated to the
chairman of the Audit Committee. In the event that the chairman is not available, the other two Audit Committee members together have the authority to grant specific pre-approval between meetings. The chairman or the other members must update the
Audit Committee at the next regularly scheduled meeting of any services that were granted specific pre-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee
pre-approved all audit related, tax and other services rendered in 2015 and did not rely on the waiver of pre-approval requirement provided by paragraph (c)(7)(i)(C) of Rule&nbsp;2-01 of Regulation&nbsp;S-X promulgated under the Exchange Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVAL</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> ARCA 2013
E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Amended and Restated ARCA biopharma, Inc. 2013 Equity
Incentive Plan, or Amended Plan, was adopted by our Board of Directors on April&nbsp;22, 2016, subject to stockholder approval. We are asking our stockholders to approve the Amended Plan, which amends and restates the 2013 Equity Incentive Plan, to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add an annual limit on director compensation to align with current corporate governance practices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increase by 1,000,000 shares the number of shares of our Common Stock reserved for issuance under the 2013 Equity Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">update and adjust certain share limits in the plan to reflect our reverse stock split in 2015 and our current determination as to appropriate annual limit levels; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make other technical revisions or otherwise non-material revisions to the Amended Plan. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of
Stockholder Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Approval of the Amended Plan will allow us to continue to grant stock awards at levels determined appropriate by
our Board of Directors and Compensation Committee. The Amended Plan will allow us to utilize a broad array of equity incentives and performance cash incentives to secure and retain the services of our employees, consultants and directors, and to
provide long term incentives that align the interests of our employees, consultants and directors with the interests of our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Amended Plan retains its provisions that are designed to protect our stockholders&#146; interests and to reflect corporate
governance best practices including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stockholder approval is required for additional shares. The Amended Plan authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares, allowing our stockholders to have
direct input on our equity compensation programs. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No evergreen provision. The Amended Plan does not contain an &#147;evergreen&#148; feature pursuant to which the shares authorized for issuance under the Amended Plan can be automatically replenished. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No discounted stock options or stock appreciation rights. All stock options and stock appreciation rights must have an exercise price equal to or greater than the fair market value of our Common Stock on the date the
stock option or stock appreciation right is granted. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No automatic single trigger vesting. The Amended Plan does not provide for automatic single trigger vesting on a change in control. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No automatic grants. The Amended Plan does not provide for any automatic grants to employees, consultants or directors. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limit on director compensation. The Amended Plan contains an annual limit on director compensation (both cash and equity-based) to reflect our commitment to current best practices in corporate governance.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stockholder approval of the Amended Plan will not affect any awards that are already outstanding under the 2013 Equity
Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We manage our long-term stockholder dilution by limiting the number of equity incentive awards granted annually. The
Board of Directors monitors our annual stock award Burn Rate, Dilution and Overhang (each as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined below), among other factors, in its efforts to maximize stockholders&#146; value by granting what, in the Board of Directors&#146; judgment, are the appropriate number of equity incentive
awards necessary to attract, reward, and retain employees, consultants and directors. The table below illustrates our Burn Rate, Dilution, and Overhang for the past three fiscal years with details of each calculation noted below the table. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2015</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2014</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>2013</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Burn Rate (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>0.84%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2.05%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13.45%</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Dilution (2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>3.08%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9.47%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13.06%</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Overhang (3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2.39%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6.59%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>7.00%</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Burn Rate is (number of shares subject to equity awards granted during a fiscal year)/weighted average common shares outstanding for that fiscal year. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dilution is (number of shares subject to equity awards + the number of shares available for future awards at the end of a fiscal year) /(number of shares outstanding at the end of the fiscal year + number of share
subject to equity awards + number of shares available for future awards). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Overhang is (number of shares subject to equity awards at the end of a fiscal year)/(number of shares outstanding at the end of the fiscal year + number of shares subject to equity awards + number of shares available
for future awards). </TD></TR></TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our request to approve the Amended Plan is approved by our stockholders, we will have a share
reserve available for grant as described below under &#147;Description of the Amended Plan &#150; Shares Available for Awards&#148;, which we anticipate being a sufficient share reserve for stock awards to be granted over a period of approximately
three years following our 2016 Annual Meeting of Stockholders. We believe that this pool size is necessary to provide sufficient reserved shares for a level of grants that will attract, retain, and motivate employees and other participants over that
time period in a competitive hiring environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If this Proposal is approved by our stockholders, the Amended Plan will become effective
on the date of such approval. In the event that our stockholders do not approve this Proposal, the Amended Plan will not become effective and the 2013 Equity Incentive Plan will continue in its current form. This will create serious constraints on
our ability to use equity-based compensation to attract, retain and motivate our employees in what is an extremely competitive hiring environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Approval of the Amended Plan by our stockholders will also constitute approval of terms and conditions set forth therein that will permit us
to grant awards under the Amended Plan that may qualify as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). Code
Section&nbsp;162(m)&nbsp;of the Code denies a deduction to any publicly held corporation and its affiliates for certain compensation paid to &#147;covered employees&#148; in a taxable year to the extent that compensation to a covered employee
exceeds $1 million.&nbsp;However, some kinds of compensation, including qualified &#147;performance-based compensation,&#148; are not subject to this deduction limitation and we believe it is in the best interests of the Company and our stockholders
to preserve the ability to grant &#147;performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of the Code. For the grant of awards under a plan to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of
the Code, among other things, the plan must (i)&nbsp;describe the employees eligible to receive such awards, (ii)&nbsp;provide a per-person limit on the number of shares subject to various types of awards, and the amount of cash that may be subject
to performance cash awards, granted to any employee under the plan in any year, and (iii)&nbsp;include one or more pre-established business criteria upon which the performance goals for performance awards may be granted (or become vested or
exercisable). These terms must be approved by the stockholders and, accordingly, our stockholders are requested to approve the Amended Plan, which includes terms regarding eligibility for awards, per-person limits on awards and the business criteria
for performance awards granted under the Amended Plan (as described in the summary below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Amended Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The material features of the Amended Plan are outlined below. This summary is qualified in its entirety by reference to the complete text of
the Amended Plan. Stockholders are urged to read the actual text of the Amended Plan in its entirety, which is appended as&nbsp;Appendix A&nbsp;to the copy of this Proxy Statement filed with the SEC, which may be accessed from the SEC&#146;s website
at www.sec.gov<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The terms of the Amended Plan provide for the grant of incentive stock options, nonstatutory stock options, restricted stock awards,
restricted stock unit awards, stock appreciation rights, other stock awards, and performance awards that may be settled in cash, stock, or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares Available for Awards </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If this
Proposal is approved, the aggregate number of shares of our Common Stock that may be issued pursuant to stock-based awards under the Amended Plan from and after its effective date will not exceed 1,259,675 shares, which is equal to the sum of
(a)&nbsp;47,654 shares remaining available for grant under the Plan prior to the Effective Date of its amendment and restatement; (b)&nbsp;an additional 1,000,000 newly reserved shares, and (c)&nbsp;any shares subject to stock-based awards granted
under the Amended Plan prior to the Effective Date of its amendment and restatement, which become available for grant under the Amended Plan from time to time due to their reversion to the Amended Plan in accordance with its terms, in an amount not
to exceed 212,021 shares (such aggregate number of shares described in (a), (b)&nbsp;and (c)&nbsp;above, the &#147;Share Reserve&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a stock-based award granted under the Amended Plan (1)&nbsp;expires or otherwise terminates without all of the shares covered by the award
being issued, or (2)&nbsp;is settled in cash (that is, the holder of the stock-based award receives cash rather than stock), the expiration, termination, or settlement of the stock award will not reduce or offset the number of shares of our Common
Stock that may be issued under the Plan. If any shares of our Common Stock issued under a stock-based award granted under the Amended Plan are forfeited back to or repurchased by us because of the failure to vest, then the forfeited or repurchased
shares will revert to and again become available for issuance under the Amended Plan. Any shares that we reacquire in satisfaction of tax withholding obligations on a stock-based award or as consideration for the exercise price or purchase price of
a stock-based award will again become available for issuance under the Amended Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;12, 2016, there were 47,654 shares
available for grant under the 2013 Equity Incentive Plan.&nbsp;As of April&nbsp;12, 2016, stock options to purchase approximately 165,264 shares were outstanding and awards other than stock options covering aggregate of 46,757 shares were
outstanding. The weighted-average exercise price of all stock options outstanding as of April&nbsp;12, 2016 was $8.35, and the weighted-average remaining term of such stock options was 8.15 years. As of April&nbsp;12, 2016, the closing price of our
Common Stock as reported on the NASDAQ Global Market was, rounded to the nearest penny, $3.50 per share, a total of 9,066,348 shares of our Common Stock were outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our employees,
non-employee directors and consultants are eligible to participate in the Amended Plan and may receive all types of awards; provided that incentive stock options may be granted under the Amended Plan only to our employees (including officers) and
employees of our affiliates. As of April&nbsp;12, 2016, we have 18 employees (including four officers) and four non-employee directors who are eligible for the Amended Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant Limits </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Amended Plan, a maximum of 300,000 shares of our Common Stock may be granted to any one participant during any one calendar year
pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise price or strike price of at least 100% of the fair market value of our Common Stock on the date of
grant. However, the Company may make an additional one-time grant of up to 100,000 shares of our Common Stock to any newly-hired employee pursuant to such awards. An option which is canceled (or a freestanding stock appreciation right that has its
exercise price reduced to reflect a reduction in the fair market value of our Common Stock) in the same fiscal year of the Company in which it was granted will continue to be counted against such limit for such fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A maximum of 50,000 shares of our Common Stock may be granted to any one participant during any one calendar year as a restricted stock award
or restricted unit award, subject to vesting conditions based on the attainment during a performance period of the performance goals described below. However, the Company may make an additional one-time grant of up to 15,000 shares of our Common
Stock to any newly-hired employee pursuant to such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The maximum amount covered by performance awards that may be granted to any
one participant in any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during a performance period of the performance goals described below) is 100,000 shares of our Common Stock in the case of performance
stock awards and $2,000,000 in the case of performance cash awards. Such limits are designed to allow us to grant awards that are exempt from the $1 million limitation on the income tax deductibility of compensation paid per covered employee imposed
by Section&nbsp;162(m)&nbsp;of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have added to the Amended Plan an annual limit on non-employee director compensation. The
maximum number of shares of Common Stock subject to stock awards granted under the Amended Plan or otherwise during any one fiscal year to any non-employee director, taken together with any cash fees paid by the Company to such non-employee director
during that fiscal year for service on the Board, will not exceed $300,000 in total value. The Board may make exceptions to this limit in extraordinary circumstances (for example, to compensate such individual for interim service in the capacity of
an officer of the Company), as the Board may determine in its discretion, provided that the non-employee director receiving the additional compensation may not participate in the decision to award this compensation or in other compensation decisions
involving non-employee directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Amended Plan is administered by our Board of Directors, which may in turn delegate authority to administer the Amended Plan to a
committee. Our Board of Directors has delegated concurrent authority to administer the Amended Plan to the Compensation Committee, but may, at any time, revert in itself some or all of the power previously delegated to the Compensation
Committee.&nbsp;Each of the Board of Directors and the Compensation Committee are considered to be the &#147;Plan Administrator&#148; for purposes of this Proposal. Subject to the terms of the Amended Plan, the Plan Administrator may determine the
recipients, numbers and types of awards to be granted, and terms and conditions of the awards, including the period of their exercisability and vesting. Subject to the limitations set forth below, the Plan Administrator also determines the fair
market value applicable to a stock award and the exercise price of stock options and stock appreciation rights granted under the Amended Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Plan Administrator may also delegate to one or more of our officers the authority to designate employees who are not officers to be
recipients of certain stock awards and the number of shares subject to such stock awards, provided that such delegation must specify the total number of shares of our Common Stock that may be subject to the stock awards granted by such officer and
such officer may not grant a stock award to himself or herself. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Amended Plan, the Plan Administrator has the authority to reprice any outstanding stock
award by reducing the exercise, purchase or strike price of the stock award or to cancel any outstanding stock award that has an exercise price greater than the current fair market value of our Common Stock in exchange for cash or other stock awards
without obtaining the approval of our stockholders prior to the repricing or cancellation and re-grant event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options may be granted under the Amended Plan pursuant to stock option agreements. The Amended Plan permits the grant of stock options
that qualify as incentive stock options, or ISOs, and nonstatutory stock options, or NSOs. Individual stock option agreements may be more restrictive as to any or all of the permissible terms described in this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The exercise price of NSOs may not be less than 100% of the fair market value of the Common Stock subject to the stock option on the date of
grant. The exercise price of ISOs may not be less than 100% of the fair market value of the Common Stock subject to the stock option on the date of grant and, in some cases (see &#147;Limitations&#148; below), may not be less than 110% of such fair
market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of stock options granted under the Amended Plan may not exceed ten years and, in some cases (see
&#147;Limitations&#148; below), may not exceed five years. Except as explicitly provided otherwise in an optionholder&#146;s stock option agreement, stock options granted under the Amended Plan generally terminate three months after termination of
the optionholder&#146;s service unless (i)&nbsp;termination is due to the optionholder&#146;s disability, in which case the stock option may be exercised (to the extent the stock option was exercisable at the time of the termination of service) at
any time within 12&nbsp;months following termination; (ii)&nbsp;the optionholder dies before the optionholder&#146;s service has terminated, or within the period (if any) specified in the stock option agreement after termination of service for a
reason other than death, in which case the stock option may be exercised (to the extent the stock option was exercisable at the time of the optionholder&#146;s death) within 18&nbsp;months following the optionholder&#146;s death by the person or
persons to whom the rights to such stock option have passed; (iii)&nbsp;the optionholder is terminated for cause in which case the stock option will cease to be exercisable immediately upon the optionholder&#146;s termination; or (iv)&nbsp;the stock
option by its terms specifically provides otherwise. A stock option term may be extended in the event that exercise of the stock option following termination of service is prohibited by applicable securities laws or if the sale of stock received
upon exercise of a stock option would violate our insider trading policy. In no event may a stock option be exercised after its original expiration date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Acceptable forms of consideration for the purchase of our Common Stock pursuant to the exercise of a stock option under the Amended Plan will
be determined by the Plan Administrator and may include (i)&nbsp;cash, check, bank draft or money order made payable to us, (ii)&nbsp;payment pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board,
(iii)&nbsp;Common Stock previously owned by the optionholder, (iv)&nbsp;a net exercise feature (for NSOs only), or (v)&nbsp;other legal consideration approved by the Plan Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted under the Amended Plan may become exercisable in cumulative increments, or &#147;vest,&#148; as determined by the Plan
Administrator at the rate specified in the stock option agreement. Shares covered by different stock options granted under the Amended Plan may be subject to different vesting schedules as the Plan Administrator may determine. The Plan Administrator
also has flexibility to provide for accelerated vesting of stock options in certain events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, an optionholder may not transfer a
stock option other than by will or the laws of descent and distribution or a domestic relations order with the approval of the Plan Administrator or a duly authorized officer. Additionally, an optionholder may, with the approval of the Plan
Administrator or a duly authorized officer, designate a beneficiary who may exercise the stock option following the optionholder&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on Incentive Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate fair market value, determined at the time of grant, of shares of our Common Stock with respect to ISOs that are exercisable for
the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. The stock options or portions of stock options that exceed this limit are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any
affiliate unless the following conditions are satisfied: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise price of the ISO must be at least 110% of the fair market value of the stock subject to the ISO on the date of grant; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the term of the ISO must not exceed five years from the date of grant. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate maximum
number of shares of Common Stock that may be issued pursuant to the exercise of ISOs granted under the Amended Plan is 1,259,675 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted
Stock Awards </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted stock awards may be granted under the Amended Plan pursuant to restricted stock award agreements.&nbsp;A
restricted stock award may be granted in consideration for cash, check, bank draft or money order payable to us, the recipient&#146;s services performed for us or an affiliate of ours, or any other form of legal consideration acceptable to the Plan
Administrator.&nbsp;Shares of our Common Stock acquired under a restricted stock award may be subject to forfeiture to us in accordance with a vesting schedule to be determined by the Plan Administrator.&nbsp;Rights to acquire shares of our Common
Stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted stock award agreement.&nbsp;Except as otherwise provided in the applicable restricted stock award agreement, restricted
stock awards that have not vested will be forfeited upon the participant&#146;s termination of continuous service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock
Unit Awards </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted stock unit awards may be granted under the Amended Plan pursuant to restricted stock unit award agreements.
Payment of any purchase price may be made in any legal form acceptable to the Plan Administrator. We will settle a payment due to a recipient of a restricted stock unit award by delivery of shares of our Common Stock, by cash, by a combination of
cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the restricted stock unit award agreement. Dividend equivalents may be credited in respect of shares of our Common Stock covered by a
restricted stock unit award. Restricted stock unit awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan Administrator. Except as otherwise provided in the applicable restricted stock unit award
agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s termination of continuous service for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock
appreciation rights may be granted under the Amended Plan pursuant to stock appreciation right agreements. Each stock appreciation right is denominated in Common Stock share equivalents. The strike price of each stock appreciation right will be
determined by the Plan Administrator but will in no event be less than 100% of the fair market value of the stock subject to the stock appreciation right at the time of grant.&nbsp;The Plan Administrator may also impose restrictions or conditions
upon the vesting of stock appreciation rights that it deems appropriate. Stock appreciation rights may be paid in our Common Stock, in cash, in a combination of cash and stock, or in any other form of legal consideration approved by the Plan
Administrator and set forth in the stock appreciation right agreement. Stock appreciation rights will be subject to the same conditions upon termination and restrictions on transfer as stock options under the Amended Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Amended Plan allows us to grant cash and stock based performance awards that may qualify as performance-based compensation that is not
subject to the $1 million limitation on the income tax deductibility of compensation paid per covered employee imposed by Section&nbsp;162(m)&nbsp;of the Code. Performance awards may be granted, vest or be exercised based upon the attainment during
a specified period of time of specified performance goals. The length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been
attained will be determined by the Compensation Committee, except that the Board of Directors also may make any such determinations to the extent that the award is not intended to comply with Section&nbsp;162(m)&nbsp;of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In granting a performance award intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of the Code,
the Compensation Committee will set a period of time, or a performance period, over which the attainment of one or more goals, or performance goals, will be measured. Within the time period prescribed by Section&nbsp;162(m)&nbsp;of the Code, at a
time when the achievement of the performance goals remains substantially uncertain (typically no later than the earlier of the 90th day of a performance period and the date on which 25% of the performance period has elapsed), the Compensation
Committee will establish the performance goals, based upon one or more criteria, or performance criteria, enumerated in the Amended Plan and described below. As soon as administratively practicable following the end of the performance period, the
Compensation Committee will certify (in writing) whether the performance goals have been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Performance goals under the Amended
Plan will be based on any one or more of the following performance criteria: revenue; gross margin; operating margin; operating income; pre-tax profit; earnings before interest, taxes and depreciation; net income; cash flow; expenses; the market
price of the stock; earnings per share; return on stockholder equity; return on capital; return on net assets; economic value added; number of customers; market share; return on investment; profit after tax; clinical trial milestones; regulatory
product approval milestones; strategic partnership milestones; customer satisfaction; and, to the extent that an Award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. In establishing a performance goal, the Compensation Committee (or the Board of Directors,
to the extent that an award is not intended to comply with Section&nbsp;162(m)&nbsp;of the Code), unless specified otherwise in the award agreement or other document setting forth the performance goals at the time the performance goals are
established, will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges, (2)&nbsp;to exclude exchange
rate effects, (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles, (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates, (5)&nbsp;to exclude the effects of any &#147;unusual or
infrequently occurring items&#148; as determined under generally accepted accounting principles, (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures, (7)&nbsp;to assume that any business divested by the Company achieved
performance objectives at targeted levels during the balance of a Performance Period following such divestiture, (8)&nbsp;to exclude the effect of any change in the outstanding shares of Common Stock of the Company by reason of any stock dividend or
split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends,
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans, (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed
under generally accepted accounting principles, (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles, and (12)&nbsp;to exclude the effect of any
other unusual, non-recurring gain or loss or other extraordinary item. In addition, the Board of Directors or Compensation Committee retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of
performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of
achievement as specified in the stock award agreement or the written terms of a performance cash award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other forms of stock awards valued in whole or in part with reference to our Common Stock may be granted either alone or in addition to other
stock awards under the Amended Plan.&nbsp;The Plan Administrator will have sole and complete authority to determine the persons to whom and the time or times at which such other stock awards will be granted, the number of shares of our Common Stock
to be granted and all other conditions of such other stock awards. Other forms of stock awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock awards granted
under the Amended Plan will be subject to recoupment in accordance with any clawback policy we may be required to adopt pursuant to applicable law and listing requirements. In addition, the Board of Directors may impose such other clawback, recovery
or recoupment provisions in any stock award agreement as it determines necessary or appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust: (i)&nbsp;the class(es) and maximum
number of securities subject to the Amended Plan, (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs, (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any
person pursuant to Section&nbsp;162(m)&nbsp;limits, and (iv)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of
a corporate transaction (as defined in the Amended Plan and described below), the Board of Directors will have the discretion to take one or more of the following actions with respect to outstanding stock awards (contingent upon the closing or
completion of such transaction), unless otherwise provided in the stock award agreement or other written agreement with the participant or unless otherwise provided by the Board of Directors at the time of grant: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the surviving or acquiring corporation (or its parent company) to assume or continue the award or to substitute a similar stock award for the award (including an award to acquire the same consideration paid
to our stockholders pursuant to the corporate transaction); </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the assignment of any reacquisition or repurchase rights held by us with respect to the stock award to the surviving or acquiring corporation (or its parent company); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accelerate the vesting (and, if applicable, the exercisability) of the stock award and, if so determined by the Board of Directors, provide for its termination prior to the effective time of the corporate transaction;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us with respect to the award; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancel or arrange for the cancellation of the stock award, to the extent not vested or exercised prior to the effective time of the corporate transaction, in exchange for such cash consideration, if any, as the Board of
Directors may consider appropriate; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make a payment, in such form as may be determined by the Board of Directors, equal to the excess, if any, of (i)&nbsp;the value of the property the participant would have received upon the exercise of the stock award
immediately prior to the effective time of the corporate transaction, over (ii)&nbsp;any exercise price payable in connection with such exercise. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors is not obligated to treat all stock awards or portions of stock awards in the same manner. The Board of Directors may
take different actions with respect to the vested and unvested portions of a stock award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of the Amended Plan, a corporate transaction will be deemed to occur in the event of
a corporate transaction or a change in control. A corporate transaction generally means the consummation of (i)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets, (ii)&nbsp;a sale or other disposition of at
least 90% of our outstanding securities, (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving
corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Control </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Amended
Plan, a stock award may be subject to additional acceleration of vesting and exercisability upon or after a change in control (as defined in the Amended Plan) as may be provided in the stock award agreement or other written agreement with the
participant, but in the absence of such provision, or action by the Board of Directors, no such acceleration will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change of
control generally means (i)&nbsp;the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction, (ii)&nbsp;a consummated merger, consolidation or similar transaction
immediately after which our stockholders cease to own more than 50% of the combined outstanding voting power of the surviving entity, (iii)&nbsp;a consummated sale, lease or exclusive license or other disposition of all or substantially of our
consolidated assets, or (iv)&nbsp;when a majority of the Board of Directors becomes comprised of individuals whose nomination, appointment, or election was not approved by a majority of the board members or their approved successors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Amendments and Termination </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
Board of Directors will have the authority to amend or terminate the Amended Plan at any time. However, except as otherwise provided in the Amended Plan, no amendment or termination of the Amended Plan may materially impair any rights under awards
already granted to a participant unless agreed to by the affected participant. We will obtain stockholder approval of any amendment to the Amended Plan as required by applicable law and listing requirements. No ISOs may be granted under the Amended
Plan after the tenth anniversary of the earlier of the date the Amended Plan was adopted by the Board of Directors or approved by our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The information set forth below is a summary only and does not purport to be complete. The information is based upon current federal income
tax rules&nbsp;and therefore is subject to change when those rules&nbsp;change. Because the tax consequences to any recipient may depend on his or her particular situation, each recipient should consult the recipient&#146;s tax adviser regarding the
federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of stock acquired as a result of an award. The Amended Plan is not qualified under the provisions of Section&nbsp;401(a)&nbsp;of the Code and
is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of
reasonableness, the provisions of Section&nbsp;162(m)&nbsp;of the Code and the satisfaction of our tax reporting obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nonstatutory Stock
Options </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, there is no taxation upon the grant of an NSO. On exercise, an optionholder will recognize ordinary income equal
to the excess, if any, of the fair market value on the date of exercise of the stock over the exercise price. If the optionholder is employed by us or one of our affiliates, that income will be subject to withholding taxes. The optionholder&#146;s
tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the optionholder&#146;s capital gain holding period for those shares will begin on that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m)&nbsp;of the Code and the satisfaction of a tax reporting
obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the optionholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Amended Plan provides for the grant of stock options that qualify as &#147;incentive stock options,&#148; as defined in Section&nbsp;422
of the Code. Under the Code, an optionholder generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the optionholder holds a share received on exercise of an ISO for more than two years from the date the stock
option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and
the holder&#146;s tax basis in that share will be long-term capital gain or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, however, an optionholder disposes of a share
acquired on exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the optionholder generally will recognize ordinary income in the year of the disqualifying disposition equal to the
excess, if any, of the fair market value of the share on the date the ISO was exercised over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the stock option, the amount
of ordinary income recognized by the optionholder will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the stock option,
that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For
purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired on exercise of an ISO exceeds the exercise price of that stock option generally will be an adjustment included in the optionholder&#146;s
alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative
minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired on exercise of an ISO is increased by the amount of the adjustment taken into account with respect to that share for
alternative minimum tax purposes in the year the stock option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not allowed an income tax deduction with respect to
the grant or exercise of an ISO or the disposition of a share acquired on exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, we are allowed a deduction in an amount equal to the
ordinary income includible in income by the optionholder, subject to Section&nbsp;162(m)&nbsp;of the Code and provided that amount constitutes an ordinary and necessary business expense for us and is reasonable in amount, and either the employee
includes that amount in income or we timely satisfy our reporting requirements with respect to that amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, the recipient of a restricted stock award (including a restricted stock award that vests based upon the achievement of performance
conditions) will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not
vested when it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which time the
recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election
with the Internal Revenue Service, within 30&nbsp;days following his or her receipt of the stock award, to recognize ordinary income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock
on the date the award is granted over any amount paid by the recipient for the stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The recipient&#146;s basis for the determination of
gain or loss upon the subsequent disposition of shares acquired from stock awards will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m)&nbsp;of the Code and the satisfaction of a tax reporting
obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, the recipient of a stock unit structured to conform to the requirements of Section&nbsp;409A of the Code or an exception to
Section&nbsp;409A of the Code (including a restricted stock unit award that vests based upon the achievement of performance conditions) will recognize ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market
value of the shares of our Common Stock received over any amount paid by the recipient in exchange for the shares of our Common Stock. To conform to the requirements of Section&nbsp;409A of the Code, the shares of our Common Stock subject to a stock
unit award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another date, unless the stock units otherwise
comply with or qualify for an exception to the requirements of Section&nbsp;409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any taxes owed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The recipient&#146;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from stock units will be
the amount paid for such shares plus any ordinary income recognized when the stock is delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of
reasonableness, the provisions of Section&nbsp;162(m)&nbsp;of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock
award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may grant under the Amended Plan stock appreciation rights separate from any other award or in tandem with other awards under the Amended
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the stock appreciation rights are granted with a strike price equal to the fair market value of the underlying stock on the
grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or cash received upon such exercise. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m)&nbsp;of the Code, and the
satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Awards </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The payment of a cash award
(including a cash award that vests based upon the achievement of performance conditions) will result in the recipient&#146;s recognition of ordinary income equal to the dollar amount received. Subject to the requirement of reasonableness, the
provisions of Section&nbsp;162(m)&nbsp;of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the cash award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All future grants
under the Amended Plan are within the discretion of the plan administrator and are therefore not determinable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Past Grants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate number of shares of Common Stock subject to stock options granted to our Chief Executive Officer, the other
named executive officers (as identified in the Summary Compensation Table, which appears in the section titled &#147;Executive Compensation&#148; within this proxy statement), and the other individuals and groups indicated, under the Original Plan
from September&nbsp;17, 2013, through December&nbsp;31, 2015, is reflected in the table below. Since its inception, no other person has been granted 5% or more of the total amount of stock options granted under the Original Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:64.40pt; font-size:8pt; font-family:Times New Roman"><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B><br><B>Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in<BR>thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. Ozeroff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officer Group (including named executive officers listed above)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-Executive Officer Director Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominee for Election as Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each associate of the above-mentioned directors, executive officers or nominees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each other person who received or is to receive five percent of such stock options, warrants or
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Group other than Executive Officer Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;0</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value in the table above represents the total pretax intrinsic value, based on the
closing price of our common stock on the NASDAQ Capital Market on December&nbsp;31, 2015, which would have been received by the option holders had all the option holders with in-the-money options exercised as of that date. Based on this analysis,
the options reflected in the table above had no pretax intrinsic value as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote and Board of Directors Recommendation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Approval of Proposal 3 requires the affirmative vote of a majority of the shares present or represented by proxy and entitled to vote at the
annual meeting. Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as &#147;Against&#148; votes. Broker non-votes are counted towards a quorum, but will have no effect on the outcome of the
vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors believes that approval of Proposal 3 is in our best interests and the best interests of our stockholders for
the reasons stated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 3. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL>&nbsp;4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DVISORY</SMALL>&nbsp;V<SMALL>OTE</SMALL>&nbsp;O<SMALL>N</SMALL>&nbsp;E<SMALL>XECUTIVE</SMALL>&nbsp;
C<SMALL>OMPENSATION</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#147;Dodd-Frank Act&#148;), and
Section&nbsp;14A of the Exchange Act, the Company&#146;s stockholders are entitled to vote to approve, on an advisory basis, the compensation of the Named Executive Officers as disclosed in this proxy statement in accordance with SEC rules. This
vote is not intended to address any specific item of compensation, but rather the overall compensation of the Named Executive Officers and the philosophy, policies and practices described in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has designed its executive compensation program to attract, motivate, reward and retain the senior management talent required to
achieve our corporate objectives and to increase long-term stockholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The compensation of the Named Executive Officers subject to
the vote is disclosed in the Executive Compensation summary below, the compensation tables, and the related narrative disclosure contained in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accordingly, the Board of Directors is asking the stockholders to indicate their support for the compensation of the Named Executive Officers
as described in this proxy statement by casting a&nbsp;non-binding&nbsp;advisory vote &#147;FOR&#148; the following resolution: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation paid to the Company&#146;s named executive officers, as disclosed pursuant to Item&nbsp;402 of
Regulation S-K, including the Executive Compensation discussion below, compensation tables and narrative discussion, is hereby APPROVED.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This vote is advisory, it is not binding on the Board of Directors. Nevertheless, the views expressed by the stockholders, whether through
this vote or otherwise, are important to management and the Board of Directors and, accordingly, the Board of Directors and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding
executive compensation arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Advisory approval of this proposal requires the vote of the holders of a majority of the shares
present in person or represented by proxy and entitled to vote at the annual meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL>&nbsp;B<SMALL>OARD</SMALL>&nbsp;O<SMALL>F</SMALL>&nbsp;D<SMALL>IRECTORS</SMALL>&nbsp;U<SMALL>NANIMOUSLY</SMALL>&nbsp;
R<SMALL>ECOMMENDS</SMALL></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A
V<SMALL>OTE</SMALL>&nbsp;I<SMALL>N</SMALL>&nbsp;F<SMALL>AVOR</SMALL>&nbsp;O<SMALL>F</SMALL>&nbsp;P<SMALL>ROPOSAL</SMALL>&nbsp;4 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECURITY</SMALL> O<SMALL>WNERSHIP</SMALL> <SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERS</SMALL> A<SMALL>ND</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principal Stockholders </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following
table sets forth certain information regarding the ownership of the Company&#146;s Common Stock as of March&nbsp;31, 2016, by: (i)&nbsp;each director and nominee for director, (ii)&nbsp;each of our named executive officers, (iii)&nbsp;all executive
officers and directors of the Company as a group, and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its Common Stock. Unless otherwise noted below, the address of each beneficial owner listed on the
table is c/o ARCA biopharma, Inc., 11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2015, the
Company completed a 1-for-7 reverse split of its Common Stock. All share amounts throughout this proxy statement have been adjusted retroactively to reflect the effects of this action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission, or the SEC. Except as
indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of Common Stock that they beneficially
own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D, Form 4s or other ownership reports filed with the SEC. For purposes of this
table, certain of our outstanding warrants that may be exercisable for fractional shares have been rounded down to the nearest whole number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In computing the number of shares of Common Stock beneficially owned by a person and the percentage ownership of that person, we deemed
outstanding shares of Common Stock subject to options, restricted stock units, or warrants held by that person that are currently exercisable or exercisable within 60 days of March&nbsp;31, 2016. We did not deem these shares outstanding, however,
for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The percentages below are based on 9,056,647 shares of our
Common Stock outstanding as of March&nbsp;31, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:74.25pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>Beneficially<BR>Owned</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="4" VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, M.D., Ph.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.73%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. Ozeroff (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Linda Grais, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Conway (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond L. Woosley (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dan J. Mitchell (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current directors and executive officers as a group (7 persons) (8)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.46%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franklin Advisers, Inc. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17.85%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Growth Equity Opportunities Fund IV, LLC (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,044,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19.90%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P. and separately managed account for which RA Capital Management,
LLC serves as investment adviser (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9.89%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sabby Healthcare Master Fund, Ltd./Sabby Volatility Warrant Master Fund, Ltd. (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.05%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tekla Life Sciences Investors (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">811,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8.96%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Venrock Healthcare Capital Partners, L.P./Venrock Healthcare Capital Partners II, L.P./VCHP
Co-Investment Holdings, LLC/VHCP Co-Investment Holdings II, LLC (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,865,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19.89%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1% of our Common Stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes the following owned by (i)&nbsp;Investocor Trust: (a)&nbsp;19,986 shares and (b)&nbsp;14,901 shares issuable upon the exercise of warrants, which warrants are immediately exercisable. Dr.&nbsp;Bristow is the
sole trustee of Investocor Trust; (ii)&nbsp;NFS as Custodian for Michael Bristow&#146;s IRA: (a)&nbsp;25,459 shares and (b)&nbsp;17,821 shares issuable upon the exercise of warrants, which warrants are immediately exercisable; (iii)&nbsp;5,578
shares issuable upon the exercise of warrants, which warrants are immediately exercisable and held directly; (iv)&nbsp;options to purchase 43,283 shares that are exercisable within 60 days of March&nbsp;31, 2016; and (v)&nbsp;2,290 restricted stock
units that are vesting within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 9,547 shares that are exercisable within 60 days of March&nbsp;31, 2016, and 1,207 restricted stock units that are vesting within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes (i)&nbsp;options to purchase 7,655 shares that are exercisable within 60 days of March&nbsp;31, 2016; (ii)&nbsp;1,145 restricted stock units that are vesting within 60 days of March&nbsp;31, 2016; and
(iii)&nbsp;1,133 shares issuable upon the exercise of warrants, which warrants are immediately exercisable. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 8,805 shares that are exercisable within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 7,354 shares that are exercisable within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 7,603 shares that are exercisable within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 6,534 shares that are exercisable within 60 days of March&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">See Notes (1)&nbsp;through (7)&nbsp;above. Also, includes additional options to purchase 90,781 shares that are exercisable within 60 days of March&nbsp;31, 2016; 39,433 shares issuable upon the exercise of warrants,
which warrants are immediately exercisable; and 4,642 restricted stock units that vest within 60 days of March&nbsp;31,&nbsp;2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on January&nbsp;8, 2016. Includes 486,746 shares issuable upon the exercise of warrants, which warrants are immediately exercisable. The warrants include a provision
prohibiting any exercise that would result in the holder beneficially owning more than 19.9% of the Company&#146;s outstanding Common Stock. The securities reported herein are beneficially owned by one or more open- or closed-end investment
companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries (each, an &#147;Investment Management Subsidiary&#148; and, collectively, the &#147;Investment Management
Subsidiaries&#148;) of Franklin Resources Inc. (&#147;FRI&#148;). When an investment management contract (including a sub - advisory agreement) delegates to an Investment Management Subsidiary investment discretion or voting power over the
securities held in the investment advisory accounts that are subject to that agreement, FRI treats the Investment Management Subsidiary as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies
otherwise. Accordingly, each Investment Management Subsidiary reports that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted. As a result, for
purposes of Rule 13d - 3 under the Exchange Act, the Investment Management Subsidiaries listed above may be deemed to be the beneficial owners of the securities reported herein. Charles B. Johnson and Rupert H. Johnson, Jr. (the &#147;Principal
Shareholders&#148;) each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. FRI and the Principal Shareholders may be deemed to be, for purposes of Rule 13d - 3 under the Exchange Act, the
beneficial owners of securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary
interest in any of such securities. In addition, the inclusion of the Principal Shareholders and FRI, as applicable, in this footnote should not be construed as an admission that any of them is, and each of them disclaims that it is, the beneficial
owner, as defined in Rule 13d - 3, of any of the securities reported herein. The address for Franklin Advisers, Inc. is One Franklin Parkway, San Mateo, CA 94403-1906. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based solely on a Form 3 filed with the SEC on June&nbsp;17, 2015. Includes 584,083 shares issuable upon the
exercise of warrants, which warrants are immediately exercisable. The warrants include a provision prohibiting any exercise that would result in the holder beneficially owning more than 19.9% of the Company&#146;s outstanding Common Stock. The
shares are directly held by Growth Equity Opportunities Fund IV, LLC (&#147;GEO IV&#148;) and indirectly held by New Enterprise Associates 15, L.P. (&#147;NEA 15&#148;), the sole member of GEO IV, NEA Partners 15, L.P. (&#147;NEA Partners 15&#148;),
the sole general partner of NEA 15, NEA 15 GP, LLC (&#147;NEA 15 GP&#148;), the sole general partner of NEA Partners 15, and the individual managers of NEA 15 GP (NEA 15, NEA Partners 15, NEA 15 GP and the individual managers of NEA 15 GP, together,
the &#147;Indirect Reporting Persons&#148;). The individual managers of NEA 15 GP are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Krishna &#147;Kittu&#148; Kolluri, Josh Makower, David M. Mott, Jon Sakoda, Scott D. Sandell, Peter W.
Sonsini, Ravi Viswanathan and Harry R. Weller. The Indirect Reporting Persons disclaim beneficial ownership within the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
meaning of Section&nbsp;16 of the Exchange Act, or otherwise of such portion of the shares of the Issuer held by GEO IV in which the Indirect Reporting Persons have no pecuniary interest. The
address for Growth Equity Opportunities Fund IV, LLC is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on February&nbsp;16, 2016. Includes 324,490 shares issuable upon the exercise of warrants, which warrants are immediately exercisable. The warrants include a provision
prohibiting any exercise that would result in the holder beneficially owning more than 9.9% of the Company&#146;s outstanding Common Stock. RA Capital Management, LLC (&#147;Capital&#148;) is the general partner of RA Capital Healthcare Fund, L.P.
(the &#147;Fund&#148;) and serves as investment adviser for a separately managed account (the &#147;Account&#148;). Peter Kolchinsky is the manager of Capital. As the investment adviser to the Fund and the Account, Capital may be deemed a beneficial
owner, for purposes of Section&nbsp;13(d) of the Exchange Act, of any securities of the Company owned by the Fund or the Account. As the manager of Capital, Mr.&nbsp;Kolchinsky may be deemed a beneficial owner, for purposes of Section&nbsp;13(d) of
the Exchange Act, of any securities of the Company beneficially owned by Capital. Capital is a registered investment adviser within the meaning of Rule 13d-1(b)(1)(ii)(E) and Rule 16a-1(a)(v), and Mr.&nbsp;Kolchinsky is a parent or control person of
Capital within the meaning of Rule 13d-1(b)(1)(ii)(G) and Rule 16a-1(a)(1)(vii). Capital and Mr.&nbsp;Kolchinsky disclaim beneficial ownership of the securities reported herein. Shares reported herein for Capital represent (a)&nbsp;the
above-referenced shares of Common Stock and shares of Common Stock issued upon exercise of the warrant (&#147;Warrant Shares&#148;) as reported for the Fund, for which Capital serves as the sole general partner, and (b)&nbsp;shares of Common Stock
and Warrant Shares held in the Account for which Capital serves as investment adviser. Shares reported herein for Mr.&nbsp;Kolchinsky represent the above-referenced shares of Common Stock and exercised Warrant Shares reported for Capital, for which
Mr.&nbsp;Kolchinsky serves as the manager. The address for RA Capital Healthcare Fund, L.P. and RA Capital Management, LLC is 20 Park Plaza, Suite 1200, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on January&nbsp;6, 2016. In accordance with Rule 13d-3 of the Exchange Act, (i)&nbsp;Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Master Fund, Ltd.
beneficially own 346,000 and 111,600 shares of Common Stock, respectively, and (ii)&nbsp;Sabby Management, LLC and Hal Mintz each beneficially own 457,600 shares of Common Stock. Sabby Management, LLC and Hal Mintz do not directly own any shares of
Common Stock, but each indirectly owns 457,600 shares of Common Stock. Sabby Management, LLC, a Delaware limited liability company, indirectly owns 457,600 shares of Common Stock because it serves as the investment manager of Sabby Healthcare
Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd., Cayman Islands companies. Mr.&nbsp;Mintz indirectly owns 457,600 shares of Common Stock in his capacity as manager of Sabby Management, LLC. The warrants include a
provision prohibiting any exercise that would result in the holder beneficially owning more than 9.9% of the Company&#146;s outstanding Common Stock. The address for Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd.
is c/o Ogier Fiduciary Services (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9007 Cayman Islands. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on February&nbsp;12, 2016. Tekla Capital Management LLC (&#147;TCM&#148;), as an investment adviser to Tekla Life Sciences Investors (&#147;HQL&#148;), shares beneficial
ownership over the shares held by HQL. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the shares beneficially owned by HQL. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote
of the shares beneficially owned by HQL, which power resides in the fund&#146;s Board of Trustees. TCM carries the voting of shares under written guidelines established by the funders Board of Trustees. The address for Tekla Life Sciences Investors
is 100 Federal Street, 19th Floor, Boston, MA 02110. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on February&nbsp;16, 2016. Venrock Healthcare Capital Partners, L.P. (&#147;VHCP&#148;); Venrock Healthcare Capital Partners II, L.P. (&#147;VHCP II&#148;); VCHP
Co-Investment Holdings, LLC (&#147;Co-Invest&#148;); VHCP Co-Investment Holdings II, LLC (&#147;Co-Invest II&#148;); VCHP Management, LLC; VCHP Management II, LLC; Anders Hove and Bong Koh are members of a group for the purposes of herein. Consists
of: (i)&nbsp;390,912 shares of Common Stock held directly by VHCP and 82,279 shares of Common Stock currently exercisable under a warrant held by VHCP; (ii)&nbsp;767,660 shares of Common Stock held directly by VHCP II and 161,577 shares of Common
Stock currently exercisable under a warrant held by VHCP II; (iii)&nbsp;71,487 shares of Common Stock held directly by Co-Invest and 15,046 shares of Common Stock currently exercisable under a warrant held by Co-Invest; and (iv)&nbsp;311,272 shares
of Common Stock held directly by Co-Invest II and 65,516 shares of Common Stock currently exercisable under a warrant held by Co-Invest II. The warrants include a provision prohibiting any exercise that would result in the holder beneficially owning
more than 19.9% of the Company&#146;s outstanding Common Stock. The address for Venrock Healthcare Capital Partners, L.P., Venrock Healthcare Capital Partners II, L.P., VCHP Co-Investment Holdings, LLC and VHCP Co-Investment Holdings II, LLC is 530
Fifth Avenue, 22nd Floor, New York, NY 10036. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECTION</SMALL>&nbsp;16(<SMALL>A</SMALL>) B<SMALL>ENEFICIAL</SMALL>
O<SMALL>WNERSHIP</SMALL> R<SMALL>EPORTING</SMALL> C<SMALL>OMPLIANCE</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16 of the Securities Exchange Act of 1934,
as amended (the &#147;Exchange Act&#148;) requires the Company&#146;s directors and executive officers, and persons who own more than 10% of its Common Stock, to file with the SEC initial reports of ownership and reports of changes in ownership of
Common Stock of the Company. Such persons are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) forms that they file. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the Company&#146;s knowledge, based solely upon its review of the copies of such reports furnished to it and written representations that
no other reports were required, during the fiscal year ended December&nbsp;31, 2015, all Section&nbsp;16(a) filing requirements applicable to its officers, directors and ten percent beneficial owners were complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XECUTIVE</SMALL> O<SMALL>FFICERS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding each of the executive officers as of March&nbsp;31, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, M.D., Ph.D.*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian L. Selby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Accounting Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. Ozeroff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Secretary, Senior Vice President and General Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Also serves as a director. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Michael R. Bristow, M.D., Ph.D.</I> See Mr.&nbsp;Bristow&#146;s
biography in Proposal Number 1 &#150; Election of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Brian L. Selby</I>.&nbsp;Mr.&nbsp;Selby has served as the Company&#146;s
Vice President, Finance and Chief Accounting Officer since December 2014.&nbsp;Previously,&nbsp;Mr.&nbsp;Selby served as the Company&#146;s Controller from 2007 to 2014.&nbsp;Prior to joining the Company, Mr.&nbsp;Selby served as the Controller for
Myogen, Inc., a publicly traded pharmaceutical company subsequently acquired by Gilead, from 2004 to 2007.&nbsp;Prior to Myogen, Mr.&nbsp;Selby served as the Controller for several private and publicly traded companies and earlier in his career was
an auditor with Deloitte&nbsp;&amp; Touche, LLP. Mr.&nbsp;Selby received his M.S. in Accounting from the University of Colorado and received his B.S., in Business Administration and Finance from Colorado State University, and is a certified public
accountant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer. Mr.&nbsp;Keuer has served as the Company&#146;s Chief Operating Officer since December 2014. Mr.&nbsp;Keuer
served as the Company&#146;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining the Company, Mr.&nbsp;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&nbsp;Keuer
served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&nbsp;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&nbsp;Keuer received his M.S. in Biochemical Engineering from Rice University and received
his B.S. in Chemical Engineering from the University of Texas, Austin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Christopher D. Ozeroff</I>. Mr.&nbsp;Ozeroff is a co-founder of
ARCA. Mr.&nbsp;Ozeroff has served as the Company&#146;s Senior Vice President, General Counsel and Secretary since 2009, has served as the Company&#146;s General Counsel and Secretary since the Company&#146;s founding, and has also served as
Executive Vice President, Business Development from 2004 to 2009. Prior to joining the Company, Mr.&nbsp;Ozeroff was a partner with the law firm of Hogan&nbsp;&amp; Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public
offerings, and licensing. Mr.&nbsp;Ozeroff completed his undergraduate degree at Stanford University and his law degree at the University of Chicago Law School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows for the fiscal years ended December&nbsp;31, 2015 and/or December&nbsp;31, 2014, compensation
awarded to, paid to, or earned by the Company&#146;s principal executive officer and its other named executive officers as of December&nbsp;31, 2015, collectively, the Named Executive Officers: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>FOR</SMALL> F<SMALL>ISCAL</SMALL> 2015 <SMALL>AND</SMALL>
2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;Name and Principal Position</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Year</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Salary<BR>($)(1)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Option<BR>Awards<BR>($)(2)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Stock<BR>Awards</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">($)(2)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Non-Equity<BR>Incentive<BR>Plan&nbsp;Awards<BR>($)(3)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">All Other<BR>Compensation<BR>($)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Total ($)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Michael R. Bristow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">296,707</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,799</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">32,225</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15,136</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">457,267</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">279,564</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">76,586</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">110,565</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21,100</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13,585</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">501,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Thomas A. Keuer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Chief Operating Officer (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">294,237</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,745</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16,357</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">394,321</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Christopher D. Ozeroff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Secretary, Senior Vice President and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">289,995</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16,110</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58,900</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,835</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">384,240</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">273,234</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15,615</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">66,690</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,350</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12,279</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">380,168</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The amounts reported under &#147;Salary&#148; in the above table represent the actual amounts paid during the
calendar year. Because the Company&#146;s actual pay dates do not always coincide with the first and last days of the year, these amounts may differ from the base salary amounts authorized by the Company&#146;s Board of Directors and described in
the narrative that follows. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The amounts reported under &#147;Option Awards&#148; and &#147;Stock Awards&#148; in the above table reflect
the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation &#150; Stock Compensation, excluding the effects of estimated forfeitures. The
value of stock option and restricted stock unit awards was estimated using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option grants and restricted stock units may be found in Note 8 to the
Company&#146;s financial statements included in our annual report on Form 10-K for the year ended December&nbsp;31, 2015, and filed with the SEC on March&nbsp;17, 2016. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Represents cash bonuses earned under the 2015 and 2014 Bonus Plans. Cash bonuses earned and reported above in
2014 were paid in 2015, and cash bonuses earned and reported above in 2015 were paid in 2016. See &#147;Executive Compensation&#148; for descriptions of the 2015 and 2014 Bonus Plans. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Mr.&nbsp;Keuer began to serve as an executive officer of the Company on January&nbsp;1, 2015.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative Disclosure to Summary Compensation Table </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreements or Arrangements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow serves as the Company&#146;s President and Chief Executive Officer under an Employment
and Retention Agreement that was amended and restated as of June&nbsp;4, 2008, and further amended pursuant to a Waiver and Amendment Agreement executed as of March&nbsp;30, 2012. Pursuant to such employment agreement, Dr.&nbsp;Bristow is permitted
to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere with his duties as President and Chief Executive Officer of ARCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2015, the Board of Directors approved a cash bonus of $21,100 for Dr.&nbsp;Bristow. The cash bonus was earned under the
2014 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2014 Bonus Plan. The Board of Directors also approved a 2015 base salary of $286,759 for Dr.&nbsp;Bristow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board of Directors approved a cash bonus of $100,400 for Dr.&nbsp;Bristow. The cash bonus was earned under the
2015 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2015 Bonus Plan. The Board of Directors also approved a 2016 base salary of $295,359 for Dr.&nbsp;Bristow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates Dr.&nbsp;Bristow&#146;s employment without &#147;cause,&#148; or if Dr.&nbsp;Bristow terminates his employment with
&#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Dr.&nbsp;Bristow a severance payment equivalent to (i)&nbsp;(a)&nbsp;12 months of his base salary, if such termination occurs on the same
day as or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does not occur on the same day as or within 13 months after a change of control of the Company, (ii)&nbsp;a pro rata
portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have
been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 6 months, whether he elects or is eligible to receive COBRA (provided, that even if he
does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in
its sole discretion, to pay additional severance equal to up to 6 months of base salary, which additional payment would extend the covenants and obligations under Dr.&nbsp;Bristow&#146;s Employee Intellectual Property, Confidentiality and
Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Dr.&nbsp;Bristow of a legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes Dr.&nbsp;Bristow&#146;s
willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or inability to perform his material job duties or
habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any
other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of Dr.&nbsp;Bristow&#146;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and the
Company&#146;s unilateral decision to significantly and detrimentally reduce Dr.&nbsp;Bristow&#146;s job responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Thomas A.
Keuer.</I> Mr.&nbsp;Keuer serves as the Company&#146;s Chief Operating Officer under an Amended and Restated Employment Agreement that is effective as of January&nbsp;1, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under his employment agreement, Mr.&nbsp;Keuer is entitled to receive an annual base salary of $280,000, subject to annual increases if
approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2015, the Board of Directors approved a cash bonus of $10,750 for Mr.&nbsp;Keuer. The cash bonus was earned under the
2014 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2014 Bonus Plan. The Board of Directors also approved a 2015 base salary of $285,600 for Mr.&nbsp;Keuer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board of Directors approved a cash bonus of $60,000 for
Mr.&nbsp;Keuer. The cash bonus was earned under the 2015 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2015 Bonus Plan. The Board of Directors also approved a 2016 base salary of $294,170 for Mr.&nbsp;Keuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates Mr.&nbsp;Keuer&#146;s employment without &#147;cause,&#148; or if Mr.&nbsp;Keuer terminates his employment with
&#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Keuer a severance payment equivalent to (i)&nbsp;(a) 12 months of his base salary, if such termination occurs on the same day as
or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does not occur on the same day as or within 13 months after a change of control of the Company, (ii)&nbsp;a pro rata portion
of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid
had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for (x)&nbsp;12 months, if such termination occurs on the same day as or within 13 months after a
change of control of the Company, or (y)&nbsp;six months if such termination does not occur on the same day as or within 13 months after a change of control of the Company, whether he elects or is eligible to receive COBRA (provided, in either
event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In
addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months of base salary, which additional payment would extend the covenants and obligations under Mr.&nbsp;Keuer&#146;s Employee Intellectual Property,
Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Keuer of a legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes
Mr.&nbsp;Keuer&#146;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or inability to perform his
material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non-Compete
Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of Mr.&nbsp;Keuer&#146;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain
exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Keuer&#146;s job responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Christopher D. Ozeroff.</I> Mr.&nbsp;Ozeroff serves as the Company&#146;s Senior Vice President and General Counsel under an Employment and
Retention Agreement that was amended and restated as of June&nbsp;12, 2008, and further amended pursuant to a Waiver and Amendment Agreement executed as of March&nbsp;30, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under his employment agreement, Mr.&nbsp;Ozeroff is entitled to receive an annual base salary of $259,000, subject to annual increases if
approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2015, the Board of Directors approved a cash bonus of $12,350 for Mr.&nbsp;Ozeroff. The cash bonus was earned under the
2014 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2014 Bonus Plan. The Board of Directors also approved a 2015 base salary of $280,273 for Mr.&nbsp;Ozeroff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board of Directors approved a cash bonus of $58,900 for Mr.&nbsp;Ozeroff. The cash bonus was earned under the
2015 Bonus Plan. See &#147;Executive Compensation&#148; for descriptions of the 2015 Bonus Plan. The Board of Directors also approved a 2016 base salary of $288,683 for Mr.&nbsp;Ozeroff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates Mr.&nbsp;Ozeroff&#146;s employment without &#147;cause,&#148; or if Mr.&nbsp;Ozeroff terminates his employment with
&#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Ozeroff a severance payment equivalent to (i)&nbsp;(a)&nbsp;12 months of his base salary, if such termination occurs on the same
day as or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does not occur on the same day as or within 13 months after a change of control of the Company, (ii)&nbsp;a pro rata
portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have
been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 6 months, whether he </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not
to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 6 months of base salary, which additional payment would extend the
covenants and obligations under Mr.&nbsp;Ozeroff&#146;s Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Ozeroff of a legal
release in a form acceptable to the Company. A termination for &#147;cause&#148; includes Mr.&nbsp;Ozeroff&#146;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially
harmful to the Company; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his
employment agreement or his Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of Mr.&nbsp;Ozeroff&#146;s normal work location
greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Ozeroff&#146;s job responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Non-Equity Incentive Plan Compensation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2007, the Compensation Committee and the Board of Directors of ARCA established a bonus structure for its entire executive team.
The philosophy employed was to create incentives for the executive officers to achieve key corporate goals. The Compensation Committee retained discretion to change the bonus structure and the bonus payment amounts as it considered appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2014 Cash Bonus Plan </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;12, 2015, the Board of Directors approved cash bonuses for certain employees. The cash bonuses were paid in 2015 for performance in 2014, including for attainment of the Company&#146;s 2014 Goals under its 2014 Cash Bonus Plan (the
&#147;2014 Goals&#148;), as determined by the Compensation Committee. The 2014 bonuses were based on the Board of Directors&#146; determination with respect to the Company&#146;s achievement of the 2014 Goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2014 Goals were based on (1)&nbsp;obtaining additional funding, (2)&nbsp;enrollment rates in the GENETIC-AF trial and (3)&nbsp;corporate
transaction objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2015 Cash Bonus Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2016, the Board of Directors approved cash bonuses for certain employees. The cash bonuses were paid in 2016 for
performance in 2015, including for attainment of the Company&#146;s 2015 Goals under its 2015 Cash Bonus Plan (the &#147;2015 Goals&#148;), as determined by the Compensation Committee. The 2015 bonuses were based on the Board of Directors&#146;
determination with respect to the Company&#146;s achievement of the 2015 Goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2015 Goals were based on (1)&nbsp;obtaining
additional funding (2)&nbsp;enrollment in the GENETIC-AF trial, and (3)&nbsp;corporate transaction objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2016 Cash Bonus Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has set corporate goals for 2016 (the &#147;2016 Goals&#148;), which may be updated at the Board of Directors&#146;
discretion during 2016. Attainment of the 2016 Goals is a prerequisite to the payment of any awards to employees under the Company&#146;s 2016 Cash Bonus Plan, including executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amount payable to each employee is set as a target percentage of each employee&#146;s annual salary, or the target bonus percentage
(&#147;TBP&#148;), but employees, including executive officers, may receive more or less than 100% of their TBP, based upon corporate goal achievement, individual performance and the discretion of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To receive a cash bonus (if any), each individual employee must be actively employed by the Company, and in good standing, on
December&nbsp;31, 2016. Employees hired after January&nbsp;1, 2016, will have their cash bonus (if any) prorated based on the percentage of time the employee worked at ARCA in 2016. The 2016 Goals are based on (1)&nbsp;enrollment of GENETIC-AF
(2)&nbsp;development pipeline objectives, and (3)&nbsp;corporate transaction objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Elements of Executive Compensation Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The remaining elements of the Company&#146;s executive compensation program, like its broader employee compensation programs, are intended to
make the Company&#146;s overall compensation program competitive with those of its peer companies, keeping in mind the constraints imposed by the Company&#146;s reliance on capital markets as a primary source of cash. The remaining elements of the
Company&#146;s executive compensation program, (401(k)&nbsp;Plan, Medical, Dental, and Vision Plans, Life and Disability Insurance) are available to all Company employees. </P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LAN</SMALL> I<SMALL>NFORMATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information as of December&nbsp;31, 2015, for all of our equity compensation plans: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;of&nbsp;Securities</B><br><B>to&nbsp;be&nbsp;Issued&nbsp;Upon</B><br><B>Exercise&nbsp;of<BR>Outstanding<BR>Options or</B><br><B>Upon</B><br><B>Vesting
of<BR>Restricted</B><br><B>Stock Units (a)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise</B><br><B>Price of<BR>Outstanding</B><br><B>Options ($)<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;of&nbsp;Securities</B><br><B>Remaining</B><br><B>Available for</B><br><B>Future&nbsp;Issuance&nbsp;Under<BR>Equity Compensation</B><br><B>Plans
Excluding<BR>Securities</B><br><B>Reflected in<BR>Column(a)</B><br><B>(c)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">223,637</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64,419</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">223,637</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64,419</TD></TR>
</TABLE></DIV> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A description of the equity incentive plans we maintain is set forth in Note 8 to the Company&#146;s financial statements included in our
annual report on Form 10-K for the year ended December&nbsp;31, 2015, and filed with the SEC on March&nbsp;17, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Risks </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance
results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. ARCA believes several features of the Company&#146;s programs reflect sound risk management practices. ARCA believes it has
allocated compensation among base salary and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting of equity awards properly accounts for the time horizon of risk.
Furthermore, the Compensation Committee assesses and monitors whether any of ARCA&#146;s compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> <SMALL>AT</SMALL>
F<SMALL>ISCAL</SMALL> <SMALL>YEAR</SMALL> <SMALL>END</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal year ended December&nbsp;31,
2015, certain information regarding outstanding equity awards at fiscal year end for the Named Executive Officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A description of the
equity incentive plans we maintain is set forth in Note 8 to the Company&#146;s financial statements included in our annual report on Form 10-K for the year ended December&nbsp;31, 2015, and filed with the SEC on March&nbsp;17, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.50pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)&nbsp;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)&nbsp;Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/23/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,035&nbsp;(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,065&nbsp;(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,985&nbsp;(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,673&nbsp;(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="10"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/2/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/25/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,194&nbsp;(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;397&nbsp;(4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;813&nbsp;(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,409&nbsp;(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff, Secretary, Senior Vice President and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,523&nbsp;(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;813&nbsp;(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,336&nbsp;(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in monthly installments through September&nbsp;17, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in monthly installments through February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in 36 monthly installments measured from February&nbsp;12, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in monthly installments through October&nbsp;15, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.50pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares&nbsp;or&nbsp;Units&nbsp;of&nbsp;Stock<BR>That Have Not Vested<BR>(#) Unvested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value&nbsp;of<BR>Shares&nbsp;or&nbsp;Units&nbsp;of<BR>Stock That Have<BR>Not Vested</B><br><B>($)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,952&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">27,677</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,075&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">28,249</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,871&nbsp;(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">31,950</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,143&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;9,965</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,429&nbsp;(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;6,645</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,664&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17,038</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,621&nbsp;(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,838</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3">Christopher Ozeroff, Secretary, Senior Vice President and General Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,571&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,605</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,664&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17,038</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,435&nbsp;(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15,973</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest on September&nbsp;17, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest in equal annual installments through February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest in three equal annual installments beginning on April&nbsp;2, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest on October&nbsp;15, 2016. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Compensation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;17, 2013, our stockholders approved the ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#147;2013 Plan&#148;) at the
Company&#146;s 2013 annual meeting of stockholders.&nbsp;The 2013 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;2004 Plan&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of the option grants and restricted stock units reported in the table above were granted to the Named Executive Officers in 2014. Each
such option grant and restricted stock unit was priced at $13.65 per share, the closing price of the Company&#146;s Common Stock on Nasdaq on the date of grant, after giving effect to the Company&#146;s reverse stock split in September 2015. The
option grants vest in equal monthly installments through February&nbsp;27,&nbsp;2018, and have an acceleration provision which provides that in the event of a Change of Control of the Company then the vesting of such options shall be accelerated as
described below. The options are subject to the terms and conditions of the 2013 Plan and the Company standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The restricted stock units vest in equal annual installments through
February&nbsp;27, 2018, and have an acceleration provision which provides that in the event of a Change of Control of the Company then the vesting of such restricted stock units shall be accelerated as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a Change in Control of the Company, the vesting of these option grants and restricted stock units accelerates as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a) Fifty percent (50%)&nbsp;of the unvested options become fully vested and exercisable upon the closing date of such Change in Control and
any remaining unvested option shares continue to vest according to the original vesting schedule, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b) Upon the one-year anniversary of
the closing of the Change of Control, or the Named Executive Officer&#146;s involuntary termination, whichever occurs first, the remaining unvested option shares shall become fully vested and exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of the option grants and restricted stock units reported in the table above were granted to the Company&#146;s Named Executive
Officers in 2015. Each of such option grants and restricted stock units were priced at $4.69 per share, the closing price of the Company&#146;s Common Stock on Nasdaq on the date of grant, after giving effect to the Company&#146;s reverse stock
split in September 2015. The option grants vest in equal monthly installments through February&nbsp;12, 2018, and have an acceleration provision which provides that in the event of a Change of Control of the Company then the vesting of such options
shall be accelerated as described below. The options are subject to the terms and conditions of the Company&#146;s 2013 Plan, as amended, and the Company standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The restricted
stock units vest in equal annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
installments through April&nbsp;2, 2018, and have an acceleration provision which provides that in the event of a Change of Control of the Company then the vesting of such restricted stock units
shall be accelerated as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a Change in Control of the Company, the vesting of these option grants and restricted stock
units accelerates as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a) Fifty percent (50%)&nbsp;of the unvested options become fully vested and exercisable
upon the closing date of such Change in Control and any remaining unvested option shares continue to vest according to the original vesting schedule, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b) Upon the one-year anniversary of the closing of the Change of Control, or the executive officer&#146;s involuntary
termination, whichever occurs first, the remaining unvested option shares shall become fully vested and exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Exercises And Stock Vested
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding option exercises and restricted stock units that vested during the year
ended December&nbsp;31, 2015, with respect to the Named Executive Officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Exercise<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized<BR>on&nbsp;Exercise<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Vesting<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized<BR>on&nbsp;Vesting<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value realized on exercise of the options equals the difference between the market price of the underlying stock at exercise and the exercise or base price of the options, multiplied by the number of shares acquired
on exercise. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The value realized on vesting of restricted stock units equals the market value of the Company&#146;s Common Stock on the vesting date, multiplied by the number of shares that vested. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal year ended December&nbsp;31, 2015, certain information with respect to the compensation of all
non-employee directors of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> <SMALL>FOR</SMALL> F<SMALL>ISCAL</SMALL>
2015 (1) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Linda Grais, M.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">45,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,645</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Raymond L. Woosley, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,645</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Robert E. Conway (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,645</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dan J. Mitchell (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,645</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Dr.&nbsp;Bristow, our President and Chief Executive Officer, was also a director during the year ended
December&nbsp;31, 2015, but did not receive any additional compensation for his service as a director. Dr.&nbsp;Bristow&#146;s compensation as an executive officer is set forth above under &#147;Executive Compensation&#151;Summary Compensation
Table.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The amounts reported under &#147;Option Awards&#148; in the above table reflect the aggregate grant date fair
value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation &#150; Stock Compensation, excluding the effects of estimated forfeitures. The value of stock
option awards was estimated using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 8 to the Company&#146;s financial statements included in our annual report on Form 10-K
for the year ended December&nbsp;31, 2015, and filed with the SEC on March&nbsp;17, 2016. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2015,
for Dr.&nbsp;Grais was 6,138, of which 6,075 shares were fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2015,
for Dr.&nbsp;Woosley was 5,063, of which 4,618 shares were fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2015,
for Mr.&nbsp;Conway was 4,941, of which 4,370 shares were fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Mr.&nbsp;Mitchell joined the Company&#146;s Board of Directors on February&nbsp;11, 2014. The aggregate number
of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2015, for Mr.&nbsp;Mitchell was 4,438, of which 3,549 shares were fully vested. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2016, the Company revised its compensation plan for non-employee directors to provide that non-employee directors will be compensated for
their service on the Board of Directors, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each non-employee director will receive an annual retainer fee of $35,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As additional compensation for their services, each non-employee director will receive (i), upon joining the Board of Directors, an initial option grant to purchase 10,000 shares of the Company&#146;s Common Stock under
the 2013 Plan and (ii), on an annual basis, an annual option grant to purchase 8,000 shares of the Company&#146;s Common Stock under the 2013 Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Chairman of the Board of Directors will receive an additional annual retainer fee of $25,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Audit Committee chair will receive an additional annual retainer fee of $15,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The chairs of the Compensation Committee and the Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each non-chair member of the Audit Committee will receive an additional annual retainer fee of $7,500; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each non-chair member of the Compensation Committee and the Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the February&nbsp;11, 2014, meeting of the Board of Directors, the Board of Directors awarded a stock option grant to purchase 2,285 shares
of the Company&#146;s Common Stock under the 2013 Plan to Dan J. Mitchell. This option vests over three years, and an additional grant of options to purchase 1,011 shares of Common Stock under the 2013 Plan vesting over one year. In addition, the
Board of Directors granted to each of Dr.&nbsp;Woosley, Dr.&nbsp;Grais and Mr.&nbsp;Conway stock options to purchase 1,142 shares of Common Stock. These options vest over one year. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price for the options issued on February&nbsp;11, 2014, was $12.60 per share, which was equal to the closing price of the Company&#146;s Common Stock on Nasdaq on the date of the grant,
after giving effect to the Company&#146;s reverse stock split in September 2015. If the non-employee director&#146;s service terminates in connection with or at any time following a change in control, then any unexpired options that remain unvested
shall become fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the February&nbsp;12, 2015, meeting of the Board of Directors, the Board of Directors awarded annual stock
option grants to the Directors. Mr.&nbsp;Mitchell, Dr.&nbsp;Grais, Dr.&nbsp;Woosley and Mr.&nbsp;Conway each were granted options to purchase 1,142 shares of Common Stock under the 2013 Plan vesting over one year. The purchase price for the options
issued on February&nbsp;12, 2015, was $4.69 per share, which was equal to the closing price of the Company&#146;s Common Stock on Nasdaq on the date of the grant, after giving effect to the Company&#146;s reverse stock split in September 2015. If
the non-employee director&#146;s service terminates in connection with or at any time following a change in control, then any unexpired options that remain unvested shall become fully vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the February&nbsp;11, 2016, meeting of the Board of Directors, the Board of Directors awarded annual stock option grants to the Directors.
Mr.&nbsp;Mitchell, Dr.&nbsp;Grais, Dr.&nbsp;Woosley and Mr.&nbsp;Conway each were granted options to purchase 8,000 shares of Common Stock under the 2013 Plan vesting over one year. The purchase price for the options issued on February&nbsp;11,
2016, was $3.44 per share, which was equal to the closing price of the Company&#146;s Common Stock on Nasdaq on the date of the grant. If the non-employee director&#146;s service terminates in connection with or at any time following a change in
control, then any unexpired options that remain unvested shall become fully vested. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL>
<SMALL>AND</SMALL> R<SMALL>ELATED</SMALL> T<SMALL>RANSACTIONS</SMALL> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions With the Company&#146;s President and Chief Executive Officer
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has entered into unrestricted research grants with Dr.&nbsp;Bristow&#146;s, the Company&#146;s President and Chief
Executive Officer, academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon the Company&#146;s financial condition, and can be deferred or terminated at the Company&#146;s discretion.
Total expense under these arrangements for the years ended December&nbsp;31, 2015 and 2014, was approximately $375,000 and $350,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Transactions With or Involving Related Persons </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2014, to which we have been a party in which the amount involved exceeded the
lesser of $120,000 or one percent of the average of our total assets at fiscal years ended 2015, and in which any of our executive officers, directors or holders of more than 5% of our capital stock, or any member of the immediate family of any of
the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements disclosed above under the heading &#147;Executive Compensation&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>June 2015 Private Placement</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2015, we sold units made up of shares of our Common Stock and warrants to purchase shares of our Common Stock in a private placement
transaction with accredited investors, including certain holders of more than 5% of our capital stock and their affiliates. We issued an aggregate of 6,003,082 shares of Common Stock together with warrants to purchase 2,401,233 shares of Common
Stock. The net proceeds to us, after deducting placement agent fees and other offering expenses, were approximately $34.2 million. Each unit consisted of one share of Common Stock and a warrant to purchase 0.4 shares of Common Stock and was sold at
a purchase price of $6.1635 per unit. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $6.1012 per share. Pursuant to the terms of the Securities Purchase Agreement entered into
as part of this transaction, we filed a registration statement for the resale of the shares underlying the units sold in this private placement. That registration statement was declared effective by the SEC on July&nbsp;20, 2015. The following
executive officers, directors or holders of more than 5% of our capital stock, or any member of the immediate family of any of the foregoing persons and their affiliated entities, participated in this transaction: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars<BR>Invested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Underlying<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Venrock Healthcare Capital Partners II, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,731,475.05</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">767,660</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">307,064</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VHCP Co-Investment Holdings II, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,918,524.97</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">311,272</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">124,508</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Venrock Healthcare Capital Partners, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,409,389.63</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">390,912</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">156,365</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VHCP Co-Investment Holdings, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">440,610.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">71,487</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">28,594</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Growth Equity Opportunities Fund IV, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,999,999.93</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,460,209</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">584,083</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Franklin Strategic Series - Franklin Biotechnology Discovery Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,946,634.63</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">478,078</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">191,231</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,553,365.75</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">738,763</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">295,505</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RA Capital Healthcare Fund, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,115,000.02</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">667,640</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">267,056</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tekla Life Sciences Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">5,000,000.26</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">811,227</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">324,491</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Audit Committee reviews and approves all related party transactions. This review covers any material transaction, arrangement or
relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, and a related party had or will have a direct or indirect material interest, including, purchases of goods or services
by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>OUSEHOLDING</SMALL> <SMALL>OF</SMALL> P<SMALL>ROXY</SMALL> M<SMALL>ATERIALS</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices
of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting
materials addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are ARCA biopharma, Inc. stockholders will be &#147;householding&#148; the
Company&#146;s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have
received notice from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish
to participate in &#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or ARCA biopharma, Inc. Direct your written request to Secretary, ARCA biopharma, Inc.,
11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020 or contact Investor Relations at 720-940-2100. The Company undertakes to promptly deliver a separate copy of the Notice of Internet Availability of Proxy Materials promptly upon
receiving your written request. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request &#147;householding&#148; of their communications should
contact their brokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>THER</SMALL> M<SMALL>ATTERS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are
properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g104091g03c53.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Secretary, Senior Vice President and General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;27, 2016 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A
copy of the Company&#146;s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December&nbsp;31, 2015, is available without charge upon written request to: Corporate Secretary, ARCA biopharma, Inc., 11080
CirclePoint Road, Suite 140, Westminster, Colorado 80020. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center">Appendix A </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>ARCA B<SMALL>IOPHARMA</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> 2013 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>RIGINALLY</SMALL> A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL>: J<SMALL>ULY</SMALL>&nbsp;26, 2013 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>RIGINALLY</SMALL> A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: S<SMALL>EPTEMBER</SMALL>&nbsp;17, 2013 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;20, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL> __, 2016 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>G<SMALL>ENERAL</SMALL>.</B> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligible Award Recipients.</B> Employees, Directors and Consultants are
eligible to receive Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Available Awards.</B> The Plan provides
for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards, (vi)&nbsp;Performance Stock
Awards, (vii)&nbsp;Performance Cash Awards, and (viii)&nbsp;Other Stock Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose.</B> The Plan, through the granting of Awards, is intended to
help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and provide a means by which the eligible recipients may
benefit from increases in value of the Common Stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>DMINISTRATION</SMALL>.</B> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration by Board.</B> The Board will administer the Plan. The
Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Powers of Board.</B> <B></B>The Board will have the power, subject to,
and within the limitations of, the express provisions of the Plan: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To determine: (A)&nbsp;who will be granted Awards; (B)&nbsp;when
and how each Award will be granted; (C)&nbsp;what type of Award will be granted; (D)&nbsp;the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock
under the Award; (E)&nbsp;the number of shares of Common Stock subject to, or the cash value of, an Award; and (F)&nbsp;the Fair Market Value applicable to a Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To construe and interpret the Plan and Awards granted under it,
and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement or in the written
terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To settle all
controversies regarding the Plan and Awards granted under it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To accelerate, in whole or in part, the time at which an Award may
be exercised or vest (or at which cash or shares of Common Stock may be issued). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#146;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection
(viii) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To amend the Plan in any respect the Board
deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or to bring the Plan or Awards granted
under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section&nbsp;409A of the Code, subject to the limitations, if any, of
applicable law. If required by applicable law or listing requirements, and except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that
(A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits
accruing to Participants under the Plan, (D)&nbsp;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&nbsp;materially extends the term of the Plan, or (F)&nbsp;materially expands the types of
Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant&#146;s rights under an outstanding Award without the Participant&#146;s
written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To submit any amendment to the Plan for
stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate
deductibility of compensation paid to Covered Employees, (B)&nbsp;Section&nbsp;422 of the Code regarding &#147;incentive stock options&#148; or (C)&nbsp;Rule 16b-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(viii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To approve forms of Award Agreements for use under the Plan and
to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not
subject to Board discretion; provided however, that a Participant&#146;s rights under any Award will not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the affected Participant, and (B)&nbsp;such Participant
consents in writing. Notwithstanding the foregoing, (1)&nbsp;a Participant&#146;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not
materially impair the Participant&#146;s rights, and (2)&nbsp;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#146;s consent (A)&nbsp;to maintain the
qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (B)&nbsp;to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified
status of the Award as an Incentive Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Option under Section&nbsp;422 of the Code; (C)&nbsp;to clarify the manner of exemption from, or to bring the Award into compliance with, Section&nbsp;409A of the Code; or (D)&nbsp;to comply with
other applicable laws or listing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ix)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, to
exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To adopt such procedures and sub-plans as are necessary or
appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or
any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(xi)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To effect, with the consent of any adversely affected Participant,
(A)&nbsp;the reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B)&nbsp;the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1)&nbsp;Option or SAR, (2)&nbsp;Restricted
Stock Award, (3)&nbsp;Restricted Stock Unit Award, (4)&nbsp;Other Stock Award, (5)&nbsp;cash award and/or (6)&nbsp;award of other valuable consideration determined by the Board, in its sole discretion, with any such substituted award
(x)&nbsp;covering the same or a different number of shares of Common Stock as the cancelled Stock Award and (y)&nbsp;granted under the Plan or another equity or compensatory plan of the Company; or (C)&nbsp;any other action that is treated as a
repricing under generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delegation to Committee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</B> The Board may delegate some or all of the administration
of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated
to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or
subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the
authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) and Rule 16b-3 Compliance.</B> The Committee may
consist solely of two or more Outside Directors, in accordance with Section&nbsp;162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delegation to an Officer.</B> The Board may delegate to one (1)&nbsp;or
more Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted
by applicable law, the terms of such Awards, and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
such Employees; <I>provided</I>, <I>however</I>, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock
Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless
otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant
to Section&nbsp;13(y)(iii) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Board&#146;s
Decision.</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Reserve. </B>Subject to Section&nbsp;9(a)
relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 1,259,675 shares, which is equal to the sum of (i)&nbsp;47,654
shares remaining available for grant under the Plan prior to the Effective Date of its amendment and restatement; (ii)&nbsp;an additional 1,000,000 newly reserved shares; and (iii)&nbsp;any shares subject to Stock Awards granted under the Plan prior
to the Effective Date of its amendment and restatement, which become available for grant under the Plan from time to time pursuant to Section&nbsp;3(b) hereof due to their reversion to the Plan, up to a maximum of 212,021 shares (such aggregate
number of shares described in (i), (ii)&nbsp;and (iii)&nbsp;above, the &#147;<B>Share Reserve</B>&#148;). For clarity, the Share Reserve in this Section&nbsp;3 is a limitation on the number of shares of Common Stock that may be issued pursuant to
the Plan. Accordingly, this Section&nbsp;3 does not limit the granting of Stock Awards except as provided in Section&nbsp;7(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if
applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reversion of Shares to the Share Reserve.</B> If a Stock Award or any
portion thereof (i)&nbsp;expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii)&nbsp;is settled in cash (<I>i.e.</I>, the Participant receives cash rather than stock), such expiration,
termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or
repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the
Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Stock Option Limit.</B> Subject to the provisions of
Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 1,259,675. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m)
Limitations.</B> Subject to the provisions of Section&nbsp;9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section&nbsp;162(m) of the Code, the following limitations shall
apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A maximum of three hundred thousand
(300,000)&nbsp;shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is
granted may be granted to any one Participant during any one calendar year, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of an Option, SAR or Other Stock Award for the purchase of up to an
additional one hundred thousand (100,000)&nbsp;shares of Common Stock. An Option which is canceled (or a freestanding SAR as to which the exercise price is reduced to reflect a reduction in the Fair Market Value of the Common Stock) in the same
fiscal year of the Company in which it was granted shall continue to be counted against such limit for such fiscal year. Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to
an increase over an exercise or strike price of at least one hundred percent (100%)&nbsp;of the Fair Market Value on the date the Stock Award are granted to any Participant during any calendar year, compensation attributable to the exercise of such
additional Stock Awards will not satisfy the requirements to be considered &#147;qualified performance-based compensation&#148; under Section&nbsp;162(m) of the Code unless such additional Stock Award is approved by the Company&#146;s stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A maximum of fifty thousand (50,000)&nbsp;shares of Common
Stock may be granted as a Restricted Stock Award or Restricted Stock Unit Award to any one Participant during any one calendar year, subject to vesting conditions based on the attainment during the Performance Period of the Performance Goals,
provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of a Restricted Stock Award or Restricted Stock Unit Award of up to an additional fifteen thousand (15,000)&nbsp;shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A maximum of one hundred thousand (100,000)&nbsp;shares of Common
Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A maximum of $2,000,000 may be granted as a Performance Cash Award
to any one Participant during any one calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation on
Grants to Non-Employee Directors.</B> The maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during any one fiscal year to any Non-Employee Director, taken together with any cash fees paid by the
Company to such Non-Employee Director during such fiscal year for service on the Board, will not exceed $300,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial
reporting purposes). The Board may make exceptions to the applicable limit in this Section&nbsp;3(e) for individual Non-Employee Directors in extraordinary circumstances (for example, to compensate such individual for interim service in the capacity
of an officer of the Company), as the Board may determine in its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
discretion, provided that the Non-Employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions
involving Non-Employee Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Source of Shares.</B> The stock
issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>E<SMALL>LIGIBILITY</SMALL>.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility for Specific Stock Awards</B>. Incentive Stock Options may
be granted only to employees of the Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may
be granted to Employees, Directors and Consultants; <I>provided, however</I>, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such
term is defined in Rule&nbsp;405 of the Securities Act, unless (i)&nbsp;the stock underlying such Stock Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code (for example, because the Stock Awards are granted
pursuant to a corporate transaction such as a spin off transaction), (ii)&nbsp;the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section&nbsp;409A of the Code, or (iii)&nbsp;the
Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ten Percent Stockholders.</B> A Ten Percent Stockholder will not be
granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL>
<SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Each
Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates
are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an
Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or
SARs need not be identical; <I>provided, however</I>, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following
provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term.</B> Subject to the provisions of
Section&nbsp;4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price.</B> Subject
to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award
is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or
substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section&nbsp;409A and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in
shares of Common Stock equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase Price for Options.</B>
The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth
below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a
particular method of payment. The permitted methods of payment are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by cash, check, bank draft or money order payable to the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pursuant to a program developed under Regulation T as
promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price
to the Company from the sales proceeds; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by delivery to the
Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>if an Option is a Nonstatutory Stock Option, by a &#147;net
exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price;
provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of
Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#147;net exercise,&#148; (B)&nbsp;shares are
delivered to the Participant as a result of such exercise, and (C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>in any other form of legal consideration that may be acceptable to
the Board and specified in the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
and Payment of a SAR.</B> To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation
distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR
on such date, over (B)&nbsp;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any
combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability of Options and SARs.</B> The Board may, in its sole
discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs
will apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions on Transfer.</B> An Option or SAR will
not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii)&nbsp;and (iii)&nbsp;below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit
transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Domestic Relations Orders.</B> Subject to the approval of the Board or
a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations
Section&nbsp;1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficiary Designation.</B> Subject to the approval of the Board or
a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to
exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#146;s estate will be entitled to exercise the Option
or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be
inconsistent with the provisions of applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting
Generally. </B>The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the
time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of
this Section&nbsp;5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Continuous
Service.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause and other than upon the
Participant&#146;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time
ending on the earlier of (i)&nbsp;the date three (3)&nbsp;months following the termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), and (ii)&nbsp;the expiration of
the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will
terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Extension of Termination Date.</B> Except as otherwise
provided in the applicable Award Agreement or other agreement between the Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause and other than
upon the Participant&#146;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the
earlier of (i)&nbsp;the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period after the termination of the Participant&#146;s Continuous Service during which the exercise of the
Option or SAR would not be in violation of such registration requirements, and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant&#146;s
Award Agreement, if the sale of any Common Stock received on exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading policy, then the
Option or SAR will terminate on the earlier of (i)&nbsp;the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service
during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable
Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disability of Participant.</B> Except as otherwise
provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her
Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve
(12)&nbsp;months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after
termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Death of Participant.</B> Except as otherwise provided in the applicable
Award Agreement or other agreement between the Participant and the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any)
specified in the Award Agreement for exercisability after the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
termination of the Participant&#146;s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option
or SAR as of the date of death) by the Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#146;s death,
but only within the period ending on the earlier of (i)&nbsp;the date eighteen (18)&nbsp;months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of such Option
or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Cause.</B> Except as explicitly provided otherwise in a
Participant&#146;s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon
such Participant&#146;s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Exempt Employees</B>. If an Option or SAR is granted to an Employee
who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6)&nbsp;months following the date of grant of the
Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;if such non-exempt Employee dies or suffers a Disability, (ii)&nbsp;upon a Corporate Transaction in which
such Option or SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement in another agreement
between the Participant and the Company, or, if no such definition, in accordance with the Company&#146;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following
the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent
permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be
exempt from the employee&#146;s regular rate of pay, the provisions of this Section&nbsp;5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> <SMALL>OTHER</SMALL>
<SMALL>THAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> SAR<SMALL>S</SMALL>.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Awards.</B> Each Restricted Stock Award Agreement will
be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company&#146;s bylaws, at the Board&#146;s election, shares of Common Stock underlying a Restricted Stock Award may be
(x)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y)&nbsp;evidenced by a certificate, which certificate will be held in such form and manner as
determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance
of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration</B>. A
Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or money order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration (including
future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting. </B>Shares of Common Stock awarded under the Restricted Stock
Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Participant&#146;s Continuous Service</B>. If a
Participant&#146;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under
the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability</B>. Rights to acquire shares of Common Stock under
the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</B>. A Restricted Stock Award Agreement may provide that any
dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Unit Awards. </B>Each Restricted Stock Unit Award
Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate
Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the
following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration.</B> At the time of grant of a
Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the
Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting. </B>At the time of the grant of a Restricted Stock Unit
Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment</B>. A
Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional Restrictions. </B>At the time of the grant
of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time
after the vesting of such Restricted Stock Unit Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend
Equivalents. </B>Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the
Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited
by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Participant&#146;s Continuous Service. </B>Except as
otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#146;s termination of Continuous Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Stock Awards</B>. A Performance Stock Award is a Stock
Award (covering a number of shares not in excess of that set forth in Section&nbsp;3(d) above) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance
Goals. A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of
whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section&nbsp;162(m) of the Code, the Board), in its sole discretion. In addition, to the
extent permitted by applicable law and the applicable Award Agreement, the Board or Committee may determine that cash may be used in payment of Performance Stock Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Cash Awards</B>. A Performance Cash Award is a cash award
(for a dollar value not in excess of that set forth in Section&nbsp;3(d) above) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may also require the completion of a
specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such
Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section&nbsp;162(m) of the Code, the Board), in its sole discretion. The Board or Committee may specify the form of
payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">12. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may
specify, to be paid in whole or in part in cash or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discretion</B>. The Board and Committee retain the discretion to
reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. Partial achievement of the specified
criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) Compliance</B>. Unless otherwise permitted in
compliance with the requirements of Section&nbsp;162(m) of the Code with respect to an Award intended to qualify as &#147;performance-based compensation&#148; thereunder, the Committee will establish the Performance Goals applicable to, and the
formula for calculating the amount payable under, the Award no later than the earlier of (a)&nbsp;the date ninety (90)&nbsp;days after the commencement of the applicable Performance Period, and (b)&nbsp;the date on which 25% of the Performance
Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such relate solely to the
increase in the value of the Common Stock). Notwithstanding satisfaction of any completion of any Performance Goals, the number of shares of Common Stock, Options, cash or other benefits granted, issued, retainable and/or vested under an Award on
account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further considerations as the Committee, in its sole discretion, will determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Stock Awards</B>. Other forms of Stock Awards valued in whole or in part by
reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant)
may be granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of this Section&nbsp;6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the
persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of
such Other Stock Awards. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&nbsp;&nbsp;C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL></B><SMALL></SMALL>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Availability of Shares</B>. The Company will keep available at all times
the number of shares of Common Stock reasonably required to satisfy then-outstanding Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities Law Compliance</B>. The Company will seek to obtain from each
regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">13. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
the Stock Awards; <I>provided, however</I>, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or
issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful
issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be
eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Obligation to Notify or Minimize Taxes</B>. The Company will have no
duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or
expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Proceeds from Sales of Common Stock</B>. Proceeds from the sale
of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Action Constituting Grant of Awards</B>. Corporate action
constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the
Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g.,
exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate
records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Rights</B>. No Participant will be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of, or the issuance of shares under, the Award
pursuant to its terms, and (ii)&nbsp;the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Employment or Other Service Rights.</B> Nothing in the Plan, any
Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time
the Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">14. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of
the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in Time Commitment</B>. In the event a Participant&#146;s regular
level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a
full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x)&nbsp;make a corresponding reduction in the number of
shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment
schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Stock Option Limitations</B>. To the extent that the aggregate
Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates)
exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted)
or otherwise do not comply with the rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment Assurances</B>. The Company may require a Participant, as a
condition of exercising or acquiring Common Stock under any Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of
exercising the Award; and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#146;s own account and not with any present intention of
selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition of Common Stock under
the Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in
the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">15. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding
Obligations.</B> Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of
such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; <I>provided, however,
</I>that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial
accounting purposes); (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Electronic Delivery</B>. Any reference herein to a &#147;written&#148;
agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet (or other shared electronic medium controlled by the
Company to which the Participant has access). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferrals</B>. To the
extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may
establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for
distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments,
including lump sum payments, following the Participant&#146;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance with Section&nbsp;409A of the Code. </B>Unless otherwise
expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the
extent not so exempt, in compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award
will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by
reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that
constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount that is due because of a &#147;separation
from service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#146;s &#147;separation from
service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">16. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clawback/Recovery</B>. All Awards granted under the Plan will be subject
to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or as is otherwise
required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or
appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback
policy will be an event giving rise to a right to resign for &#147;good reason&#148; or &#147;constructive termination&#148; (or similar term) under any agreement with the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>A<SMALL>DJUSTMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization Adjustments</B>. In the event of a Capitalization
Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3, (ii)&nbsp;the class(es) and maximum number of securities that may be issued
pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c), (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any person pursuant to Sections 3(d), and (iv)&nbsp;the class(es) and number of
securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dissolution</B>. Except as otherwise provided in the Stock Award
Agreement, in the event of a Dissolution of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of
repurchase) will terminate immediately prior to the completion of such Dissolution, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, <I>provided, however,</I> that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer
subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Transaction</B>. The following provisions will apply to Stock
Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by
the Board at the time of grant of a Stock Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board will take one or more of the following actions with respect to Stock Awards, contingent upon
the closing or completion of the Corporate Transaction: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">17. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;arrange for the
surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an
award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction); </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;arrange for the assignment of any reacquisition or repurchase
rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company); </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accelerate the vesting, in whole or in part, of the Stock Award
(and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board will determine (or, if the Board will not determine such a date, to the date that is five days
prior to the effective date of the Corporate Transaction), with, if so determined by the Board, such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;arrange for the lapse, in whole or in part, of any reacquisition
or repurchase rights held by the Company with respect to the Stock Award; </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cancel or arrange for the cancellation of the Stock Award, to the
extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make a payment, in such form as may be determined by the Board
equal to the excess, if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B)&nbsp;any exercise price
payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:9%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board need not take the same action or actions with respect
to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:9%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in Control</B>. A Stock Award may be subject to additional
acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the
Participant, but in the absence of such provision, or action by the Board, no such acceleration will occur. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>P<SMALL>LAN</SMALL> T<SMALL>ERM</SMALL>; E<SMALL>ARLIER</SMALL> T<SMALL>ERMINATION</SMALL>
<SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:9%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary
of the earlier of (i)&nbsp;the date the Plan is adopted by the Board (the &#147;<B></B><B><I>Adoption Date</I></B><B></B>&#148;), or (ii)&nbsp;the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan
while the Plan is suspended or after it is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">18. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Plan will become effective on the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The law of the State of Colorado will govern all questions concerning the construction, validity and interpretation of this
Plan, without regard to that state&#146;s conflict of laws rules. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>D<SMALL>EFINITIONS</SMALL>. </B>As used in the Plan, the following definitions will apply to the
capitalized terms indicated below:<B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B></B><B><I>Affiliate</I></B><B></B>&#148; means, at the time
of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or
&#147;subsidiary&#148; status is determined within the foregoing definition.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B></B><B><I>Award</I></B><B></B>&#148; means a Stock Award or
a Performance Cash Award.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B></B><B><I>Award
Agreement</I></B><B></B>&#148; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B></B><B><I>Board</I></B><B></B>&#148; means the Board of
Directors of the Company.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;</B><B><I>Capital
Stock</I></B><B>&#148; means each and every class of common stock of the Company, regardless of the number of votes per share. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B></B><B><I>Capitalization Adjustment</I></B><B></B>&#148;
means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger,
consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of
shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding
the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Cause</I></B>&#148; will have the meaning ascribed to
such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;such
Participant&#146;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; (ii)&nbsp;such Participant&#146;s refusal, unwillingness, failure, or
inability to perform material job duties or habitual absenteeism; or (iii)&nbsp;such Participant&#146;s violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of any contract between the Participant
and the Company. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">19. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect
upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B><I></I></B><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>&#147;Change in Control</I></B>&#148; means the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events:<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>any Exchange Act Person becomes the Owner, directly or indirectly,
of securities of the Company representing more than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the
foregoing, a Change in Control will not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any
affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity
securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase
or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the
Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting
securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>there is consummated a merger, consolidation or similar
transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly,
either (A)&nbsp;outstanding voting securities representing more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than fifty percent
(50%)&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting
securities of the Company immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>there is consummated a sale, lease, exclusive license or other
disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries
to an Entity, more than fifty percent (50%)&nbsp;of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of
the Company immediately prior to such sale, lease, license or other disposition; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">20. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>individuals who, on
the date the Plan is adopted by the Board, are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however</I>, that if the appointment
or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of
the Incumbent Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing definition or any other provision of the Plan, the term Change in
Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and the definition of Change in Control (or any analogous term) in an individual written agreement
between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; <I>provided, however</I>, that if no definition of Change in Control or any analogous term is set
forth in such an individual written agreement, the foregoing definition will apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Code</I></B>&#148; means the
Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Committee</I></B>&#148;
means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Common Stock</I></B>&#148; means
the common stock of the Company, having one vote per share.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Company</I></B>&#148; means
ARCA biopharma, Inc., a Delaware corporation.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(m)&nbsp;&nbsp;&nbsp;&nbsp;</B>&nbsp;&#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is
(i)&nbsp;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However,
service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only
if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Continuous Service</I></B>&#148;
means that the Participant&#146;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an
Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will
not terminate a Participant&#146;s Continuous Service ; <B><I></I></B><I>provided, however</I><B><I></I></B>, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole
discretion, such Participant&#146;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that
party&#146;s sole discretion, may determine whether Continuous Service will <B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">21. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or
(ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the
Company&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Corporate
Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a sale or other disposition of all or substantially all, as
determined by the Board, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a sale or other disposition of at least ninety percent
(90%)&nbsp;of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a merger, consolidation or similar transaction following which the
Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into
other property, whether in the form of securities, cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Covered
Employee</I></B>&#148; will have the meaning provided in Section&nbsp;162(m)(3) of the Code.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Director</I></B>&#148; means
a member of the Board.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Disability</I></B>&#148;
means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or
can be expected to last for a continuous period of not less than twelve (12)&nbsp;months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems
warranted under the circumstances.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>Dissolution</I></B><B>&#148;
</B><B><I></I></B>means when the Company, after having executed a certificate of dissolution with the State of Delaware, has completely wound up its affairs. Conversion of the Company into a Limited Liability Company will not be considered a
&#147;Dissolution&#148; for purposes of the Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Effective Date</I></B>&#148;
means the effective date of this amended and restated Plan document, which is the date of the annual meeting of stockholders of the Company held in calendar year 2016, provided the Plan is approved by the Company&#146;s stockholders at such
meeting.<B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">22. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>&#147;Employee</I></B>&#148; means any person employed by the
Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Entity</I></B>&#148; means a
corporation, partnership, limited liability company or other entity.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Exchange Act</I></B>&#148;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Exchange Act Person</I></B>&#148; means any natural
person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or
(v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more
than 50% of the combined voting power of the Company&#146;s then outstanding securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Fair Market
Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows:<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is listed on any established stock exchange or
traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, <U><B>the closing sales price</B></U> for such stock as quoted on such exchange or market (or the exchange or
market with the greatest volume of trading in the Common Stock) <U><B>on the date of determination</B></U>, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided by the Board, if there is no closing
sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the absence of such markets for the Common Stock, the Fair
Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Incentive Stock
Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Non-Employee
Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as
a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not <B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">23. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
be required under Item&nbsp;404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#147;<B><FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT></B>&#148;)), does not possess
an interest in any other transaction for which disclosure would be required under Item&nbsp;404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation
S-K; or (ii)&nbsp;is otherwise considered a &#147;non-employee director&#148; for purposes of Rule 16b-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Nonstatutory Stock
Option</I></B>&#148; means any option granted pursuant to Section&nbsp;5 of the Plan that does not qualify as an Incentive Stock Option.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Officer</I></B>&#148; means
a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Option</I></B>&#148; means
an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Optionholder</I></B>&#148;
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Other Stock
Award</I></B>&#148; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a
written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Outside
Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee of the Company or an &#147;affiliated corporation&#148; (within the meaning of Treasury Regulations promulgated under Section&nbsp;162(m) of the Code), is not a
former employee of the Company or an &#147;affiliated corporation&#148; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an
&#147;affiliated corporation,&#148; and does not receive remuneration from the Company or an &#147;affiliated corporation,&#148; either directly or indirectly, in any capacity other than as a Director, or (ii)&nbsp;is otherwise considered an
&#147;outside director&#148; for purposes of Section&nbsp;162(m) of the Code.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Own,</I></B>&#148;
&#147;<B><I>Owned,</I></B>&#148; &#147;<B><I>Owner,</I></B>&#148; &#147;<B><I>Ownership</I></B>&#148; means a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired
&#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting,
with respect to such securities.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Participant</I></B>&#148;
means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.<B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">24. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;Performance Cash
Award&#148; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Performance Criteria</I></B>&#148; means the one or
more criteria that the Board or Committee will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or
combination of, the following as determined by the Board or Committee: (i)&nbsp;revenue; (ii)&nbsp;gross margin; (iii)&nbsp;operating margin; (iv)&nbsp;operating income; (v)&nbsp;pre-tax profit; (vi)&nbsp;earnings before interest, taxes and
depreciation; (vii)&nbsp;net income; (viii)&nbsp;cash flow; (ix)&nbsp;expenses; (x)&nbsp;the market price of the Stock; (xi)&nbsp;earnings per share; (xii)&nbsp;return on stockholder equity; (xiii)&nbsp;return on capital; (xiv)&nbsp;return on net
assets; (xv)&nbsp;economic value added; (xvi)&nbsp;number of customers; (xvii)&nbsp;market share; (xviii)&nbsp;return on investment; (xix)&nbsp;profit after tax; (xx)&nbsp;clinical trial milestones; (xxi)&nbsp;regulatory product approval milestones;
(xxii)&nbsp;strategic partnership milestones; (xxiii)&nbsp;customer satisfaction; and, to the extent that an Award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the Board or Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Performance Goals</I></B>&#148; means, for a
Performance Period, the one or more goals established by the Board or Committee for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units,
divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board or Committee
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board or Committee will appropriately make adjustments in
the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of
changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of any unusual or infrequently occurring items as determined under generally
accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a
Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,
merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based compensation and the
award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11)&nbsp;to
exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles and (12)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary
item. In addition, the Board or Committee retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use
for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">25. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Performance
Period</I></B>&#148; means the period of time selected by the Board or Committee over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a Stock
Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Performance Stock
Award</I></B>&#148; means a Stock Award granted under the terms and conditions of Section 6(c)(i).<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Plan</I></B>&#148; means
this ARCA biopharma, Inc. 2013 Equity Incentive Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of
shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a
written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Restricted Stock Unit Award</I></B>&#148; means a right
to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Restricted Stock Unit Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be
subject to the terms and conditions of the Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Rule 16b-3</I></B>&#148;
means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Securities
Act</I></B>&#148; means the Securities Act of 1933, as amended.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Stock Appreciation
Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Stock Appreciation Right
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the
terms and conditions of the Plan.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Stock Award</I></B>&#148; means any right to receive
Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">26. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(aaa)&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Stock Award
Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>(bbb)&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any
corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such
corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the
Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B><B>(ccc)&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I></I></B>&#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a
person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than ten percent of the total combined voting power of all classes of stock of the Company or any Affiliate.<B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">27. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV STYLE="position:relative;float:left; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g104091pcpg001a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:24pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Using a <B><U>black ink</U> </B>pen, mark your votes with an <B>X </B>as shown in this example. Please do not write outside the designated areas.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:2%; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g104091pcpg001b.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:12pt"><B>Electronic Voting Instructions</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Available 24 hours a day, 7 days a week!</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:8pt">Instead of mailing your proxy, you may choose one of the voting methods outlined below to vote your proxy.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:8pt">VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:8pt"><B>Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Mountain Time, on June 9, 2016.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4">&nbsp;


<IMG SRC="g104091pcpg001c.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>Vote by Internet</B></P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">&#149;&nbsp;&nbsp;Go to
<B>www.investorvote.com/ABIO </B></P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">&#149;&nbsp;&nbsp;Or scan the QR code with
your smartphone</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">&#149;&nbsp;&nbsp;Follow the steps
outlined on the secure website</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Vote by telephone</B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">&#149;&nbsp;&nbsp;Call toll
free 1-800-652-VOTE (8683) within the USA, US territories &amp; Canada on a touch tone telephone</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">&#149;&nbsp;&nbsp;Follow the
instructions provided by the recorded message</P></TD></TR>
</TABLE></DIV> </DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104091pcpg001d.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT
STYLE="font-family:ARIAL"><B></B></FONT><B> IF YOU HAVE NOT VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px dashed #ff00ff">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#ffffff"><B>&nbsp;A&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Proposals &#151; The Board of Directors recommends a vote <U>FOR</U> the nominee listed and <U>FOR</U> Proposals 2, 3 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>and 4.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1. Election of one director to hold office until the 2019 Annual Meeting of Stockholders.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL; font-size:8pt"><B>For</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL; font-size:8pt"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"><B><FONT STYLE="font-size:24pt">+</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL; font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;01 - Dr. Linda Grais</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL; font-size:16pt"><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL; font-size:16pt"><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD></TR>

<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Abstain</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">2.&nbsp;To ratify the selection of KPMG LLP as the Company&#146;s independent registered public accounting
firm for the fiscal year ending December 31, 2016.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">4.&nbsp;To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers as
disclosed in the proxy statement.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:2%; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD></TR>

<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Abstain</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">3.&nbsp;To approve the Amended and Restated ARCA 2013 Equity Incentive Plan.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:16pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR></TABLE>
</DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">In their discretion, the proxies are also authorized
to vote upon such other matters as may properly come before the Annual Meeting. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>

<TR STYLE="page-break-before:always; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#ffffff"><B>&nbsp;B&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Non-Voting Items</B></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Change of Address </B>&#151; Please print your new address below.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Comments </B>&#151; Please print your comments below.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Meeting&nbsp;Attendance</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="font-size:16pt">&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Mark&nbsp;the&nbsp;box&nbsp;to&nbsp;the&nbsp;right if&nbsp;you&nbsp;plan&nbsp;to&nbsp;attend&nbsp;the</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">Annual Meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#ffffff"><B>&nbsp;C&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign </B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Below</B></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>

<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Please date and sign exactly as the name appears on this card. Joint owners should each sign. Please give full title when signing as executor, administrator, trustee, attorney, guardian for a minor, etc. Signatures for corporations
and partnerships should be in the corporate or firm name by a duly authorized person.</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>

<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>Date&nbsp;(mm/dd/yyyy)&nbsp;&#151;&nbsp;Please&nbsp;print&nbsp;date&nbsp;below.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature 1 &#151; Please keep signature within the box.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature 2 &#151; Please keep signature within the box.</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt"><FONT STYLE="font-family:ARIAL; font-size:24pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:8pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104091pcpg001f.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:14%; font-size:8pt; font-family:ARIAL">02BT5D </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Important notice regarding the Internet availability of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>proxy materials for the Annual Meeting of Stockholders. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>The ARCA biopharma, Inc. Annual Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>and
ARCA biopharma, Inc. Notice of Annual Meeting are available at: www.edocumentview.com/ABIO </B></P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B> IF YOU HAVE NOT VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE. </B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px dashed #ff00ff">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g104091pcpg002a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Proxy &#151; ARCA BIOPHARMA, INC. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="justify"><B>PROXY SOLICITED BY THE BOARD OF DIRECTORS
OF ARCA BIOPHARMA, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="justify"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE&nbsp;9, 2016 </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The undersigned hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement of ARCA biopharma, Inc. (the
&#147;Company&#148;) in connection with the Company&#146;s Annual Meeting of Stockholders to be held at the Boulder Marriott Hotel, 2660 Canyon Boulevard, Boulder, CO 80302, at 9:00 a.m., Mountain Time, on Thursday, June&nbsp;9, 2016, and does
hereby appoint Michael R. Bristow, M.D., Ph.D., Thomas A. Keuer and Christopher D. Ozeroff, and each of them (with full power to act alone), as proxies of the undersigned with all the powers the undersigned would possess if personally present and
with full power of substitution in each of them, to appear and vote all shares of Common Stock of the Company which the undersigned would be entitled to vote if personally present at the 2016 Annual Meeting of Stockholders, and at any postponement
or adjournment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The shares represented hereby will be voted as directed herein. <B>IN EACH CASE, IF NO DIRECTION IS INDICATED, SUCH SHARES
WILL BE VOTED &#147;FOR&#148; THE NOMINEE LISTED AND &#147;FOR&#148; PROPOSALS 2, 3 AND 4. AS TO ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF, SAID PROXY HOLDERS WILL VOTE IN ACCORDANCE WITH
THEIR BEST JUDGMENT. THIS PROXY MAY BE REVOKED IN WRITING AT ANY TIME PRIOR TO THE VOTING THEREOF.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>PLEASE VOTE, DATE AND SIGN ON THE REVERSE
SIDE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Please be sure to sign and date this Proxy. </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g104091g03c53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091g03c53.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>T4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   " &@ .$))300E       0M^[+80\(9WI8H*S9
M&NFJ,CA"24T$.@     !=0   !     !       +<')I;G1/=71P=70    '
M     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$
M00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M
M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    (@!< %P 4 !( %@ 1@!"
M %4 +0!- %< 10 M $8 4  Q #  7 !! %H ,  Q #4 ,0 M %@ 10!2 $\
M6  M #$ .       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$")4
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))300-       $    'CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             !U@  !E4
M     0                         !              95   !U@
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !U@    !2
M9VAT;&]N9P  !E4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   =8     4F=H=&QO;F<   95
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M   /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E
M;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T
M;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E
M=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M     C_P        .$))3004       $    !#A"24T$#      -BP    $
M  "@    +@   >   %9    -;P 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ +@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ ]2JJJHJ932QM5530RNM@#6M:T;6,8QOM:QK5-)))2E@]5S\7
M/JS\2QSJ^D8E+W=6R]CRU]8%K<G P[&M+;7L;3=7U*ZC?=B?T2C]>N]?I]CJ
MF=GORJ^E=*9.2_TWYF42UK<7&L-K?M#&VBS[1EW?9LBK"J;3=2R_]+G?J_LR
M!#HK[LVNA[?2Z+@;+,?'#G>I?F"QN9]OR+V7>I=539_@\O\ 29F?9E967ZGI
M8E]B4V/JY@6].Z/3AV-=6*W6^C2]YL=50ZVRS#Q7VEUNY^)B/IQO;;=7^B_1
M76U?I%IJIU/J-'3L5U]SZV$RVH6N+&.?#GP^QC+GUU,8Q]V3?Z5GV7%JORK?
MT-%BQ_JKTO*-N1]8^J>L>I=3:UK:LAK&.Q\=A/I8U53/4=BLR'?K=N+ZUGH_
MH:,E^1EX]V9DI3T:2222E))*CU/J;<%M===;LG,R7!F-C,#B7$N96ZZYU;+7
M8^%CNMK^V9GI[,=G^DNLIIM2E=3ZFW!;7776[)S,EP9C8S XEQ+F5NNN=6RU
MV/A8[K:_MF9Z>S'9_I+K*:;5T<=:&$#UMV,[-+B2,)MC:FM_,:'9+WVV/_/<
M_P#1?Z/T_P!'ZMBZ;TNK"=?DNVVY^:YMF;E!H8;'-;Z536L]WIX^/4/2QJ=]
MFQG\[;?DV9&1=/J>=]AQ76L9Z^2^68F*#M==<0YU6.QT/V;]GZ2W;Z>-1ZN5
M?^KTVO24U^B9O4,D9N/U$4_:NGY)QW6X^YM=C373F46MJM-CZ'^AEU,MJ]:_
M],Q_Z9::#BTOIH;78_U+=76/]T%[B;+36VZS(LJJ]1SO1H]:S[/5^@K_ $=:
M,DI22222E+/ZQUS"Z174<@^ID9-C*L7$8ZL77/>^O'VX[,BRAC]C[ZW6_I/T
M5:AU/KN+@Y%>!6UV5U3(:'48=;7N.TO9C_:<JRFN[['A,MM_395S?H,M]%E]
MM?HK"S,ZCZLV'J&71D=;^M'4JVUNHQ6FW8 RRYN'BPQOV'I7K8V2^K]'9F9/
MIWY-OVVS%O\ 12GHNDU=7KQW.ZOD4Y&58X/VX]9KJJ&RMCL>GU'VW7,]9EMO
MKW>]_J_S=7\VKR222G__T/55G]0ZKZ%WV#!;7E]6?6+Z\)UGI?H?5JQKLFV[
M9=Z-5/K;_P";]2_TK*\>NU6,_-JP,5V3:'/ <RME;(+GV6O;CX]+-Q8S?=?;
M75NM?73_ *:RNKWJOT;!RL:@W]2?7?U3)]V9?4"&:%SJ<7'%A<]N)B,L]*C_
M $GZ7+L9]JRLA)3+I/3&].QW-=8[(RLAPNS<EQ=-U^RNFR_TWOL;CL>VEGIX
MU/ZOCL_14HV;U#"Z?4+LRYM-;G;0YWC!>[^Q74RR^^SZ%&/5=DW>G13;8@]3
MZI5@-KK;MMS<EPKP\3<&OM<7,K<X#WV_9\;U?7S;JJ;OLN+ZE_I/6$,&SJ#\
MB[J>9^KXMF[-RI8:#2UU]V;]7Z7654L;T_$?5@LZKU#9ZG5/2NP<STOLWV;"
M2DN!3U+KF?5U>U_V;IK+&68^/]-SQ4W(;5;1=79LQ_4?E_K>7C^I5U2C]0J]
M;I-?[0ZWTRQ\+ZW?5S.R+<?&S6N=139DOL<U[*O0J?\ 9[LFO+M8S%NQZ[FN
M9ZU5SZU:NZET^WI;\ZG,;]E>TMKR\8MN]Q/H,^S;6Y#,C(]?]%31Z5_JY'Z#
MT;?YM)3>253I5[+^FXUC,ROJ/Z,-?FU;=EKV?H[KFB@OJ9OM8_\ 1UN_1_S:
MMI*0Y651AT.R,AVRID28+B2XAE===; ZRVVVQS:Z::V^K=;^BJ_2*ETG$S2Y
MW4NJ;?MV0T>G2!IB5.;6Y_3V/%EK+G^NS?E9E?I?;7^E[/0QL2JFOU+[+D=?
MPJ,[TQC85?VNIM\-:_+LLKPL&W%+OYZW"WWUVL_P-_4NF?SF191Z,ZNN6]4:
M3T"IN11N<P]2N);B@L<:K?L[6_K'47U/][?1]' R?TE?[5JN24Z&7GXN&['9
M>YP=EW#'H:UC["ZQS7V[8I;9L8VJFVRRVS]#4QGZ1ZKXN&_(O;U+/J]/);/V
M:C>YPI806M]2OU7X7[0VON];*QZOT=5_V&O(R<=GVC)J5X#^F>D_'Q_VIUR^
MLMNS[W.K:0W8_)]3+<W,^P8EEWZ3'Z7AL?5Z]GZOB^A7E9-&;]8\>KIG1+\_
MK9;U_J3W&K Q;:@<=U]SBW!QL3H_JNJL?3O]U^[(ZK]F^T_K7I_H4E/6K!L^
MNWU<95]H&0ZS%#K&.R*JWV-!K%CRYK*F/ONQWLQ<Y]>=13;@?J&9^M?HE5=]
M47=5Z+C](ZI?=C]+QZ6548%+FMMVUU^A0_J>6SU*LO(IVU9;*<6NC"IR_P"<
M_:=55-RU<CZN=(MZ1E='HH;@X>8US;6X0&.9< QU@] -;OVM;NWM>RUGZ*[U
M:?T:2G0NNJHJ?=<]M5532^RQY#6M:T;GO>]WM:QK5S_5?K#U:PTXOU<Q&W9F
M0UKP_.9?2VMIL=4Y^1C>BV^AFRC)L_7G].]?_O-_:5WJXRJ_62GZI?5ZK&S+
M,-KNI.N'[.JJ8Z^^_+CTZLJ_%]:AW5,C'==ZOVC,O]=EEWZ')KR\K]+:Z']6
M!0:\S-:UMMC6796.UE8]7,;9?D.ZEGVTASK\C=>VVG!]>[IW2\C^A_:/1Q,J
MI*<KH=;>GX]-/2<O)S<KK5+LVSJV30ZS*R6T,9CFG#&5Z#<1E;=EF%D=;N^Q
M4_:\6NG]I?:[?LVUT3ZM58EK<_-II&<QUIIKJBRNGU2*[;J\FRFC-R\W+QJ,
M;[?GY[KLBV[UO1]&BZRI"P.E_6'".<ZMN$[-R[@YW5;G/LMM8RQE./\ :\+&
MQL"IK\;I7Z-E>/ELI^UL_P"[5]RN_L7*R?=U3J.1=.OH8A.%2UP]K7U'$?\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %^34T *@    @ # $   ,    !!I@   $!  ,
M   ! GH   $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5
M  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (
M  $Q  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (
M  @ >YB@   G$ ![F*   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-CHP-#HR-2 Q,SHU.3HR,@     $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   95H , !     $   '6          8! P #
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M   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @
M"  (   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,38Z,#0Z,C4@,3,Z-3DZ,C(     !)    <    $,#(R,: !  ,
M   !__\  * "  0    !   &5: #  0    !   !U@         & 0,  P
M  $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X , # 1$  A$! Q$!_\0
M'0   @(# 0$!              D'" 4&"@0! O_$ "X0  $$ P "  4#! (#
M      4#! 8' 0((  D1$A,5%A07(1@B(S$9)"@R0?_$ !0! 0
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MNAR4(3DP2XX[)J;K0;$/R /8$?=A7<<D,M2:'7*$=5R22=??&X,@\ \ \ \
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+ / / / / / __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g104091pcpg001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg001a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ P@$L P$1  (1 0,1 ?_$ ,D  0 !!0$!
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M1@[>=Q@PBA/*Y)FZW$=%4=,K,>\9$1+ZUH2:-_"YEIN!W'N;RZRI:945TI#
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MLENVU 59#'+*BM-:[FRXVZ*GR)6UO8K>F@*(T1(:R\A*<0Y#J:WC1+"+;:<
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MA9.52"? 5$!%24E1+*2\U]:VJ >T H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M;")VA>@)W9> WGC9,Z;*QW3EIC-#KKDGJ.3LG?4;ET?<:Z1$G<4VP($+3:U
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M-&MK+%KZ=7[L/ C?WF;L_*_^ZQ']JK\"OVDZO_Q.6W?].M^!V6,9.1FC+WC
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MK&_44=2!:_O:>-O164,\[AVB8>R>[>:ENW-S&<B"0)BI'+#Y9^[1(HJ]'Z2
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M=4C=1+)I)-*KK1 .Z=TKM$FE>/"H=&C._*:E4VUL_L\L5B2%4.84 H!0"@%
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MTB<(@1XR<:,6Q5M$4K&*HO96:B&<5'IY-1*,LN'A,8Y5#4X]3[39ZQ/)% *
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MZ$XU7AJ&8KD:JMVW-JNR7[N+?V:[S8ZR/,% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#7\S^C9;]!_&1_TCW?N/Q_K_
M *'V*UIM6T]+EOFI\^RVSO\ E^\U%?\  HG^ _I)^]^*_%#[WK_I?>6K?I_:
M/8_UK?S_ )5V[7]E_>DV[+_X[A/T+F7X[\;R3\3_ #>NU85^5[3Q^7_DZGS]
MVSO^VPV"LCS10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g104091pcpg001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg001b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ EP$L P$1  (1 0,1 ?_$ ,0  0 " P$!
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MS%_6GJJ>_'K/F60_G;/YEW[$5CA?\SS?[7CWU6IGW?XO.IXG^7CU7_M+3/\
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M*J ?4W7S>0_V40[5H>*&K2Z]*?\ <EN4B<DJW1/1HB W8KT?AW/1,M_&-?\
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MD8P)!CDY*&+#Y"2.%=%'%PW47YG'"+Y56I%N+X>#E3;X&P9@9(]Z.C_-N#S
M#Q+#XC<IY)!SW+68>3DQVHD* Y&;;<(4;)QUA#($3L4D);_+46+<3&+C7Z5/
M)N L7+-@RA$F4YO3%A)E]+X--F2XV4*4\;Y-3S;;4U4M((RTJ"E_)<EKEO
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M5IX?Q>E='&>Y/M\1YIK>?^F_)/NC$?6'J@]\=<O,J#^>L_FW?LQ6.*_S3/\
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MU'.5'95EIH'(34^0CD@1=$76R=4&VM*JZHB'6RI4[FGC6AY41$ER=LQ&S2A
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M*XX6)S*QX#CK_AWV",#===5P7+"ZWWFT)4&]TOWNVUK;P5IBMAS"!SDQ.:8
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MJ-H"AQKV*)<LC$&$I'>M,C4T'\=<I;Q+4G.\@S&6=*AM>$FQWI.'!LRW"VG
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MVT+/\X9 ],./BT=S0.2&Y,)7T%L!C"!D8O:%U:T>;T=Q/6ZVLM1NAB]%7Y;
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M'QQ.1F(X2LL1.H)QP-PVB$102W# FC4DNG1/34[FK/U+0<IVLLIM(R,84[U
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M!)%+4JNHT.U9.NOR58R<OIK1;7>($I[PB49QWK0RER^9O(YS=2UR<5)D8EB
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HF4G-7P(_VK3B;T9W7EGC^'..U$X#">'K>MJDZ^FUQKY5*(E$2B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g104091pcpg001c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg001c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ .P [ P$1  (1 0,1 ?_$ *$   (# 0$!
M      4& @0' 0,  0 !!0$!               "  $#!08$!Q    4# @,%
M!@0#"0       0(#! 41$@8 $R$Q%$$B,A4'46$C,S060E)R-7&!0Z&Q8E-C
M@R4F%Q$  0," P8$! 4$ P       1$" P $(3$205%A,A,%<2(S%(&Q4B.1
MH4)B<O#!\16"HG3_V@ , P$  A$#$0 _ &&-C<8#&'V2Y*^EP )==@0C!</9
M>7NG_GVZZ22J"O2IY[CW#8(&Q>D'>8?#97#1V"RN+3\ECS^<!W#-RK4>+E @
MBH(@7@6HCX1KRTE(.*4XFNX;B*.=L.F1R>4;JUM%W/CA$,ECZS,9Q1DT.5-^
M8UID]HMYJ%&\1]^H<%QK&NCA]W(9@_I![N7>N'"E#(8E:-<QL]D+Q1/,I!P"
M3%-JL8(DKA(*("L4]#@G:!=R@^W1@[!E5U9W E:^&!H-LQJNU#[FD\VE,%ST
MU2PO/G..O\@+D;-Z\=O'QE2JQR!UVO *&VC','<$?#3LTG,5$J?N?:&W+(N@
MYC6M8GG(#OCQWU8R>)CYOU*F0E'3U".CX5.0$C-7;/\ #H)N U#PB/#VZ32@
MJ.QN'P6,?3:PO?,6>8+G0#'&_I7D$RUB&+[(RNG8F!(55B%)W2"<:B%W87V:
M-VH!<*L+U_<+>)TKVV^ENX'PI:Z)7I:]<[KYEY=\XWR>HI7]?OT2U:]4:N5O
MIZ\MNGY4=CS8M*X*_P >DI]O#.PG%W@;Q14$2 6T.Z EYB/M[-"5!7A5?,+B
M&[;/'$Z1O1#<,*XV;8;C>&Y2U;92UE74JU(F@@F0R9KDS&&@5,>M;],221A2
M>^ZNKJ!SH'1MC<222N=.!\?5?R6*/8S)$H>:1@6Y2-10!90[<"W'.%P@6WF'
M+0KFHJE%X(V3LDA,D1G=BJ .V"H9YFD%+KL&JV+'R2)<+ G#OTW(I)KN#%M.
M1,"@ U*:I>(]FDUJ;4HNT]LFA#G";HR >=I:I:W8OSJ#_():&]-YIW%RH).6
M*S9%O&E(0QXH@G(061S& VX) &VX=( %U/#9QSWT;9&*UX<2Y3]W G6-RYI4
M9F5AFWJ3/)3$@G'IR6/$:$<J\MQ8 #D'.G.FD!A\:>VMY76,1B87EDY<@W"E
MS"X# \<R5A,GS=DY*S$XB@")B":Y,Q/%>:GBKRT3G$A$JS[G=WES Z(6SVZM
MJ\5W4N^:QO2?4D_>>JY_T.I^9^G1)5G[>35D?2T_'3E6@N<I9P.4JQ^9XO%(
M,SHF<(N&+,'"AA,H($O$:AQ IA-H-*C UG&6#KBW#[6:4N5"'/TC+%/RH\^3
M:RT+'RV$8["/&SG<,X\P031$A2FM+0H ',P&YZ'(XFJZ(NAE?'=RS-<U$T.)
M_K90@,^EB8L^EG$/')S<6_"&2*BF80*W[I3[9JWV@)AI:-NG+,:[3VF,W#8V
MR2&*1G4*G]7'8OCC0AQ!9)@&0-$(=)":B'RR;>&&34W00<#WSJ%*2PJ(WB/?
M#3J'#&NUEW!W&%QE+HI& E^@)J;L&*ZL-E1EU\\/FT<V<1<.5T]275-'$4$6
M3H2@(F5=%NH=0O,HF[=((E/;LLQ:/<U\NEI:-2>=O!FX';3?/9UZ>'Q@<D6C
MV[Q=4RC-J+AH10PN$B&$I#U 3 G4M*UT+6E4JEM.U7HN.@'N: CBCB/*3^"T
MG8GZIX4ND[/E&.Q[44Q)TPL6 *%$! ;[Q-=3C2FC<P[#5UW#L-TTM%O+(Y57
M4]/PK4-GT]I3RMC3I.MITJ--FM?R\Z]FHO-64U7OUOY]/,[.LY7]5)-7$E".
MI5N$J>:%DNB)4BG\M'NG$24X%_QTK[]2=/&M,WL$8N06L=T^CJ!Q3J>/]J.N
M\"@64"=[AR?5P+U,WG+!N<[A1^BF-$TT%!,<2"4PFJ)1T.H[:KX^[3/F#+HZ
M9FGR.(#0PG,N&W9G5#)8^8QW&4,H.H!)=,Z#&**8E#-(Q>@ T5(;NG4( B G
M$*^_3@J4KILIHKF<VX'VSJ<_'FD'ZP=@.[*F>05P_'8HN'-6AG$6>]*6126$
M19-G%3G7<G,83D3&\1NKH<25JJA;<W,GNG.23-A(YW-R:W83A68>JT#Z<8_'
M-4(2/.=W)HE<LI(CDZB()@<M>Z8Q@-<7EJ6-SB<:U78+N^N'N,KQI84<W2 5
M3PV&JF-8 T=H1S.>CEH)X+LAE9)^*B2+Q$QJ S1*(E^*8!J AQX:=S]U37O=
MW,+W0O$K=)\K4)8?K=^T5J$9Z:XYCD;DR,LND3&)4Z!@2.H=/932$: =8QJ\
M3F#C74)>2F^LI/WN>Y?"8P>O&'; 5)W#PK)_L1QTUOECB[JZTH?]MW[MW]%.
M-^IM=;#_ &K=7.WDX>IIR\>%-V$,,%+B,B]R-H@95U,N8]N\.@"RI3J@&V "
M!3"%!J(=F@<2N%4W=);OW+&0.<C8FO(U($&=5GB&,XJX/CY_4"88'84(+1%-
M3;)> *=VPHEXWUX:04XI4L;KB[:)A:Q/U[20IV;?"BV2Y'#Y/C;=H+Y4V)-A
M00>Y$)#]5UZ=+""B8+C;@"4PG *5'3!I!XUQ65E+:SEVD>X=J+8\-.@YG5PR
M2O![.XW 2.08CDCHVZX9%0/DATSK/G ."76JVE-P2*>A:]@:<-)0BI(K2>X9
M%<P-P#UZ:HQND[/Y)C2DSD< :9;"B\F%Y_'6C99)4K]N<Q$.X())D2$OAK3D
M'#1HY#OJYDAO'VTFF-L,SG ^5PQQQ)*U9SS,H%QB<;'0\^[EI%G(]85VX(HF
MJ0H$/;:8Q2^ PA;33,85Q%1=I[;,VY>^6)L;'1Z4!!!Q'SHW&A+24+!X]*2K
MJ01SI$ZB[AP<5#L^D^* ( -0'<'@:NA.T[JX)^G%++/&QK#:' ##7JP\WALK
MG_G7JOLT\Q=WW=%]4G]#NUN\?Y/P:6MM/_N>W+R-^KE/.GAOVU?ALD]1YB.=
MR:<O"1L:@^5:$ZY/;^(GQ#C02U$!]M=,6@5S7-E8PO;&8YGO+ [RE<#4I69]
M26T-(3"4]CTDG'I[SDC0@+*4Y!R#A7LJ.D .--;VUBZ5D1BG87E!J*"@WJ'!
M2.2RF..E%4F#5>&0</'RUR+3>,(G,2\ $@'-=W0T3'(M=W9KMEK',T O<)2
MT8N3)4S0;:&XCD<3#SK]S$,G+./G4DV4*^DP Z*3DO QUE3")1(4_.T1$ T[
MFDBNKN-E)-"ULKFN?$2Y[69ENYHWIOKQ]2V&#LF15"*^897(E!PY>L5R*,BK
M7AO]P!J4#=ZP*:>,GX4?9);N1R$:+=F :YI#T3RX_.M-FIIB9C,_\S#J1"D0
MJFT9IJI=5U0I" B(@/$!X@ !QKJ$ K65MK9X?']N7J=4*4.G2M*^"+LVV/1,
MY,ND91["(_\ 7X>-.47Q2K )%B*H5 5#TH;W  CHW;A5MW5KG320Q-,;93]Q
M[QY,,6D.V"F_JO5"SYS6^WKJ["E.EN^GY?/M[- C:I>GV]<G?3S#F^K^-9ZW
MQR9R#TK?,8AJ+MT7(UE12 Q"]PI*"-3B4/Q!J34 ['=6D?>Q6_<&OE=I;[<#
M\^%0@,+R7',#S<TRP,S*Y9(@@(G3-<)#'$W@,;E<'/2<X$A**\[G!<WEMTG:
MM+RN>U-]/<NPALEPB%Q!:1Z.27C6C]),$S*&,D@D%1_"7F'YM "A6L_;RRVM
MW)<AFI@D<W-,2?Q_*D3TQ9M9>/CHY=,,D0*L/5PZWPTXM(ZIJNBF'YHG :VA
MHY,#6@[Y(Z%[W@]$I@\8F0IR\$WUZI1F)0S+.)1U MY(D3+ V9M5!$@$2.<"
M6E, &H 5KRTE)0+0.GN9WVT;97,ZD2DYXHM4<L]*XC#_ "67>2'5Q[J102=H
M*(V$(@:JAZB4QQ$ *40I33MD5171V_O\M[U(FLTO;&X@KMR&S?3:R]/F822<
MEB) %C.B*S.>1*"9HDA"T $DU# 97?J)1Y4T&O#&J:7O#NF67)\\6!C./57>
M1EISVTG_ '3GO3W?<KJ[K_+JT)_GV[O\:=FCTC=5W["SU>BWDU_]<J$LNEW7
MU?,J]6M^W=1L^+MI^+VZ(UV2ZD;Z?*.?2O\ BHRW2>6N/WCP#]7U.Q_N>[3"
ME;ZM8]+_ (Z5^%:A';?WOBG@K]K!3QUI:/+LI_'CJ(Y'QK*3+[2?_P!/"E_!
M-GRC#_!3S$UG0;N_7>-]7V[7LNT3\S5EW9>I/GZ?ZD3E_1^[PK[(=G[7]2*[
M=/.T[J[E*[Y?%3C7].DW,4K-?<6F?HG=]--[S;^^UZ;5_ER%?,[^AI4ORJ]W
M=_MI70#*J6-?:#/U#R)K^/[:(>G5GG&26W7;Z%UE_1^$_P!+=PL]M-,ZN;O*
@]*'P/\MG/QK(O@=+_2_?O];GU']^IJV>.K;Z'#Z:_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g104091pcpg001d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg001d.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ (0+& P$1  (1 0,1 ?_$ *\  0 " P$! 0
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MMA=1K,N5FATDDE>H$HD!3#W@.8HG$VK3ZQHKWZJ\E H% H% H% H% H% H%
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B@4"@4"@4"@4"@4"@4"@4"@4"@ZV7[A__ /&#_P"PC0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g104091pcpg001f.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg001f.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ *P+& P$1  (1 0,1 ?_$ ,@   $$ P$!
M       $!08' 0(#" D! 0 # 0$!               ! @0#!080  $# @0"
M! <- P@'"0$   (! P01!0 2$P8A%#$B!S=!43*R(Q5U87&!L3-SLS1T-387
M"$+#%J%2<L)#)(1VD=%B@I)3.**#DT1D)64FIA@1  $# 00$"0D' P,%
M  $ $0(#(3$2!$%1<1-A@<$B,G(S!361H;'10L)S- 928H)#@Q05\)(CXE-T
MX?&BLF/_V@ , P$  A$#$0 _ /5."(P1&"(P15OVU/O-1]M:3A-YKNP)954:
MHJ+P6F-65'2V+Z?Z9B":SA_\11M=]XNVC=C1.$K018Z@VI*HHJ@UT)T)B:@_
MQ13/1 [KH%K<4O3)5QNV;-'MS1D9#@L^LH*::&2#149JE*TQKI1&YXBOI^[J
M43W2[!]W/WEF\S9J=O(,I(<1GUM%330RRT56^%*TQ$ -SQ*,M2C_ !#L'W4N
M5/=WERD<[5J/.)I<II4(NI4U\GCP^#'.(',XU@R].+9&P6XO0E<:5)_B;LN'
M6/*[;D5U,RT)='I+CQ^'%2.;/:N4X1W&=L%E3E39^HR9+8OUI1A]QI%B&JH!
M$**NHOB7%\B 8E:OHRG&5&;@'G<B:>V2;-:3:NE(=;SV9@BRF257QK1>G%\L
M!SMJV?3=*)W[@=K)3AN1(_-#9S>J>F=AS&&9<JEI.\53PKC.W^.76]2\ PC_
M !^8+6[_ )8J%%-F?DF+O,.ZOK[+J9RS9<B\*UK3&AAOOPKW12C_ "K,&W.K
MA4_[?WWV=B139<)HUG,HI 2BM-)WPIC-D@\^)?._2,!+-R!#\P^F*KNYSIJ=
MA]G>20ZCJW9U%<SEF5,KO!5K7&J(&^.Q?2T*4/Y:H&#;H:.JG%F9,_+#93FN
MYJ'?<IGG*I#JN<%6O%,4(&\EU5FE3C^_S 8-N>0)XD2I/K[M436.C4&K29EH
M*Z2\1X\,<P+(;5BA3CN<E8+9\J?8+[Z]@1/*X6MZK>74S+FK4N.;IQS(_P W
M&O/JP'\PS6;P<BKOLZG33V#OPSD.D;<5A6R(R517TO0JKPQKKQ&.*^E[YI1&
M<RP '2EHZJUV).FGV:[Z<.0Z3C;47(:F2J-2/H6O#"N!O(\:GO6E 9[+  7R
MT;%+K-)DKO?LY!734'+&A."I+0ET'.))7BN.$QS)]9>-F81_:9LL+*WO!/?8
MB^^[#W&KKA.*-V>$<Y*5$RCP2N.6:%HV+!]41 E28-_B"KOLCFS7>UC3<D.&
MW69U",E'@)4X*N->9 W2^E^H:41W<X ?F<B.Q6;-=[23;=D..-Z,KJ$9$G#W
M%7#-@;M/J:E$9%P +8K S9OY76ISF'=1=R*"GG+,HZ:\*UZ,&&\/54FE'^0F
M&#?M]7"K&L+[R]N>XV5<)6AMS*BVI+E1:,<43HQEF/\ "-OK7S.;B/XFB6MW
MA]Y5UOZ;-#ML1H)#@M<[ 330R0:*+->%:8U40-SQ%?2]TTHGNIR ^"?O+&\I
MLT.W%&1D."UZQ@)IH9(-%1FJ4K3$THC<\14]VTHGNEV#[N?O*17F5*2]]J*(
M\:(U"85I$)>JN0?)X\,<8@-!>9EJ<=UDK!;.7I6K,J5S_90FL='62U4S+U_(
M\KCQ^' @-44RIQP9ZP6'UKE^HZ7*8N5D1AYQI"9?S(!*->N'31<3D0""K_1E
M.,H5' -HY5=L!56!&5>*JT''_=3'GRO7PE;IG:5WQ"YJ(787KYO-=OOR'F+3
M"@!-D,QW"9*0Z\Z38";@*)Z8"VJT%4JJ\>C'>/-ABTNO:RY%#*[X &I*>$$A
M\( !+ V.73O8; ]9GY3;4YV1:W<A1(<@B=..2(J.(+QD1D!<%02Z,4G/%HM6
M+-YL5A$F(%0.Y%F+58+'&O2N.]DO:[?EE:I80B;9><D25%3=0 ;(J,I5!0U5
M*9EZ/?PI-BM5^[-UOH[R.*T,-#OIX.#2DT:!+NVSK$)7!V&RL>*]<70(A=>:
M1A%-O60D(,Q44B3C2OCQ8D1F;%VG5C1S57F"1Q2$=0.*]M+: FW;,>=<H-]C
MVFY26+$\ZVU9+@X1/NH(BB2B8-U5(FU*HMDJKQJJ<*8O4(!#BW2M.>G"E.E*
MI")J@$SC</NX@+'^T.(K3;=RCVS<5ZC./2H-GA0VY'+W1QPW%4#-'I3).J9:
M*IE1>MY7@3"I%XC27T*V=H2JT*<@(RJRF0\ &N#1+-SK]%VE;[:N=YF[Y=D3
MG#9C3;6DB%;26B,M<QE;4QK\J8]8_%7+X,*D0(6:U7.T*4,H! /*-1I2UG#:
MWW1<-=^E-5M?F1KFW=-Q1;S&;E7)P&9)2R&(VKD@ABMG%%S,C:CE&I!2J^+%
MY $-%KOZM6NO",J9IT)4I&-,.,/.+1YQ$FOO-ZX7&\OS)=]N4E;LTW:ISD5N
MXP31(T!J/E'.K"N!KYEJ;O4*@K3$QBP #6CRKK1RPA&E".Z)J0$L,NE,R^\W
M-U1M%J?M^V]I8[4F),F^M[HXU"MC3$Q]EC5<3Y56VR0<K8(3A>.F.5&6@@,.
M!>=W36.(QE&&[I@RD\(DL-#D7D\T)-N9MRWR-NV5U^X72$+#_-Q8;KG//FV(
M9)#I 0$K8KFKUTZRCTXFG:YL'H77(R%2-6J!3IRQ18R P1=WB'>WB-@*0#>)
MKFT]O%=+B\U:7IS[-ZFBX0OLL@KN@Q)=%!)LLR V\7#CX>-<7PC$6%K6+0<M
M 9FKNX U! &$6YI/-Q2B+CIE$>9:CN5](5ZM5HN#SD%+C;H5LN)&3CC;-P(
M=TW3J1H"Y],UK[ZT3#=V@D6L?,I.2&.G4JP GNZDI1N!,'9P+GLQ!26S-G:-
MYOV)A]YVVOVX)S34ATWR:=!Y6G,IN*1Y30A6BKTIPQRGSH8M+KR\R16RHK$
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MD%?!P\<[H-:N@[LIB/.)Q-;;I&)V#6W7.$[+N5WUE=(HBVC<5@SB.N(0 3C
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M$B][K(L6+7WBWB6EOW9+FS1-HV5AD^# QU D?)''' S(N?@K>GUAR^ L3*D
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MEYJ,$1@B@[&QKD),"X\V#;!KI$VM2 ''PDN40P(557$+I3Q8TFL%[\^]:=K
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MRN?YC-5NGD^@S>+]GQXB+[G3=P*,OO/XKV\.[E_MX=/XN5/%UY#4[3,W)_\
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3T'?)I_<LOO\ 6^&F"E7-@H7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g104091pcpg002a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104091pcpg002a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 2P#- P$1  (1 0,1 ?_$ (4   $% 0$!
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M"C38L/!0(T;)(#>09:C-(0^@7LEU*4@+'J/ T'*/TZZ?QTZ6-M8ML>"8<?\
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M0-N8P(^[\''M_!0<4]-.G:4+0G;.+"'%H<<0(;&E2VPH(41IM=(<5;VF@DE
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MN\T'3,XY>1Q[D1+W)YA3J7;5< W(M<=M!VA1$160VDE:N&M9[20+=@X  "P
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B_P#8(][W1_:>_P#O>=17N@* H"@* H"@* H"@* H"@__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
